Functional Role of Aspartate-31 and Leucine-32 in Mycobacterium Avium Dihydrofolate Reductase by Bock, Ronnie A
FUNCTIONAL ROLE OF ASPARTATE-31 AND 
LEUCINE-32 IN MYCOBACTERIUM AVIUM 
DIHYDROFOLATE REDUCTASE 
 
 
By 
RONNIE A. BOCK 
Bachelor of Science in Biology  
Universität des Saarlandes 
Saarbrücken, Germany 
1990 
 
Master of Science in Biology  
Universität des Saarlandes 
Saarbrücken, Germany 
1996 
 
 
 
Submitted to the Faculty of the 
Graduate College of the 
Oklahoma State University 
in partial fulfillment of 
the requirements for 
the Degree of 
DOCTOR OF PHILOSOPHY  
May, 2006  
FUNCTIONAL ROLE OF ASPARTATE-31 AND 
LEUCINE-32 IN MYCOBACTERIUM AVIUM 
DIHYDROFOLATE REDUCTASE 
 
 
 
 
Dissertation Approved: 
 
 
Dr. W. Barrow 
____________________________________________________________________________________________________________________________________________  
Dissertation Adviser 
 
Dr. J. Malayer 
____________________________________________________________________________________________________________________________________________  
 
Dr. K. Clinkenbeard 
____________________________________________________________________________________________________________________________________________  
 
Dr. R. Burnap 
____________________________________________________________________________________________________________________________________________  
 
Dr. G. Emslie 
____________________________________________________________________________________________________________________________________________  
Dean of the Graduate College
ii 
ACKNOWLEDGEMENTS 
I would like to express my sincere gratitude and appreciation to my supervisor and 
mentor Dr. William Barrow for the opportunity to work with him and his lab and to share 
in and benefit from their experience.  Dr. Barrow’s advice and guidance enabled me to 
not only complete my doctoral program, but prepared me for a new world of science and 
research. I will always be thankful for his patience and support.  
I am thankful to my other committee members Dr. J. Malayer, Dr. K. Clinkenbeard and 
Dr. R. Burnap for their advice and interest. Their time in reading through my proposal 
and this dissertation, their input and suggestions and critical questioning during our 
meetings is highly appreciated.  
I would also like to acknowledge Esther Barrow, our lab manager, for creating the best 
working and learning atmosphere. Her patience and willingness to invest her time and 
energy in me, by sharing with me her knowledge, introducing me to everyone and by 
listening to me and answer all my questions, will forever be remembered. I am 
particularly grateful to her for showing such a genuine interest in my personal welfare 
and later that of my family. I am also thankful to our lab members Dr Michelle Valderas 
and Dr. Phil Bourne for all their valuable help and support during my entire program. 
Phil’s help in preparing some of the graphic images in this dissertation and during other 
presentations is greatly appreciated 
My thanks and appreciation also goes to Dr. Jose Soulages, Department of Biochemistry 
and Molecular Biology at OSU, for his help and support in all experiments and analysis 
iii 
regarding circular dichroism.  I am in debt to Ms Betty Handlin from CVHS at OSU for 
her ever friendly technical help in preparing this dissertation and her support and 
friendliness during my stay at OSU. 
My research project was funded in part by NIH grant AI-41348  (PI Dr. William Barrow) 
and by the Sitlington Chair for Infectious Diseases, CVHS at OSU (Sitlington Professor 
Dr. William Barrow). My graduate studies and stay in the United States were funded by a 
scholarship from the Namibian Government, administered by the Africa-America-
Institute (New York). I would also like to acknowledge the Staff Development Program 
of the University of Namibia, for granting me study leave for the duration of my doctoral 
program in the United States. 
Last, but not least, my heartfelt appreciation and thanks goes to all my family, 
particularly my loving and supporting wife, Barbara and my dearest children Raoul, Lizle 
and Sharifa, for their love, support, understanding and all the sacrifices they had to 
endure during my studies. I dedicate this work to them all. 
 
 
 
iv 
TABLE OF CONTENTS 
CHAPTER I Introduction ................................................................................................... 1 
Background................................................................................................................. 1 
Objectives ................................................................................................................. 11 
Hypothesis 1.......................................................................................................... 11 
Hypothesis 2.......................................................................................................... 15 
Chapter 2 Materials and Methods ..................................................................................... 19 
Bacterial strains used ................................................................................................ 19 
Mycobacterium avium DHFR gene (folA) ................................................................ 19 
Plasmid vector construct p807 for recombinant M. avium DHFR............................ 19 
Validation (Verification) of recombinant wild type M. avium DHFR...................... 20 
Transformation...................................................................................................... 20 
Overnight cell growth ........................................................................................... 20 
Plasmid DNA extraction ....................................................................................... 21 
Determining plasmid DNA concentration and purity........................................... 22 
Restriction endonuclease digestion and agarose gel electrophoresis.................... 22 
Sequencing............................................................................................................ 23 
Pilot expression of recombinant wild type M. avium DHFR.................................... 23 
Transformation...................................................................................................... 23 
Growth and IPTG induction.................................................................................. 23 
BugBuster protein extraction ................................................................................ 24 
Polyacrylamide gel electrophoresis (SDS-PAGE)................................................ 25 
Separating gels .................................................................................................. 25 
Stacking gels ..................................................................................................... 25 
SDS sample buffer ............................................................................................ 26 
Electrophoresis running buffer ......................................................................... 26 
Site-directed mutagenesis ......................................................................................... 26 
Design and synthesis of mutagenic oligonucleotides ........................................... 27 
5’-Phosphorylation of mutagenic oligonucleotides .............................................. 28 
Mutagenesis reaction ................................................................................................ 28 
Alkaline denaturation (dsDNA)............................................................................ 28 
Agarose gel electrophoresis .................................................................................. 29 
Oligonucleotide hybridization .............................................................................. 29 
Mutant strand synthesis and ligation..................................................................... 31 
Transformation of BMH 71-18 mutS (repair-minus strain).................................. 32 
Transformation and over night growth ............................................................. 32 
Plasmid DNA extraction ................................................................................... 32 
Determination of plasmid DNA concentration and purity................................ 32 
Transformation of JM109 ..................................................................................... 33 
Transformation.................................................................................................. 33 
v 
Overnight cell growth ....................................................................................... 33 
Plasmid DNA extraction ................................................................................... 34 
Determining plasmid DNA concentration and purity....................................... 34 
Sequencing........................................................................................................ 34 
Large scale protein expression of recombinant mutant DHFR............................. 34 
Transformation.................................................................................................. 34 
Overnight cell growth and IPTG induction ...................................................... 34 
BugBuster protein extraction ............................................................................ 35 
BioRAD protein determination (microassay procedure for microplates)......... 36 
Polyacrylamide gel electrophoresis (SDS-PAGE)............................................ 37 
Purification of recombinant mutant and wild type DHFR (semi-automated 
procedure) ............................................................................................................. 37 
His-Resin and column preparation (manual operation) .................................... 37 
Loading and washing the column (manual operation)...................................... 38 
Biologic LP chromatography system (BioRAD).............................................. 38 
Elution (automated procedure) ......................................................................... 39 
Functionality of recombinant mutant DHFR ........................................................ 40 
DHFR standard enzyme assay .......................................................................... 40 
Kinetic assay ..................................................................................................... 41 
IC50 determination............................................................................................. 41 
Growth complementation.................................................................................. 43 
Circular dichroism ............................................................................................ 46 
CHAPTER III Results....................................................................................................... 48 
Mutagenesis .............................................................................................................. 48 
Protein expression and purification .......................................................................... 49 
Aspartic acid 31 mutations........................................................................................ 53 
Specific activity .................................................................................................... 53 
Kinetic characteristics of D31 mutant DHFR....................................................... 56 
Growth complementation...................................................................................... 58 
Leucine 32 mutations................................................................................................ 61 
Specific activity .................................................................................................... 61 
Kinetic characteristics of L32 mutant DHFR ....................................................... 63 
Growth complementation...................................................................................... 65 
Inhibitor IC50 assay ............................................................................................... 66 
CHAPTER IV Discussion................................................................................................. 71 
Functionality of M. avium conserved aspartic acid 31 (D31) mutants ..................... 72 
Functionality of M. avium conserved leucine 32 (L32) mutants .............................. 80 
Chapter V Conclusion....................................................................................................... 89 
REFERENCES ................................................................................................................. 90 
 
vi 
LIST OF TABLES 
Table 1. IC50 for trimethoprim for DHFR of various organisms. ....................................... 4 
Table 2. Comparison of overall amino acid sequence identity in DHFR of various 
species. ................................................................................................................. 6 
Table 3.Mutations of D31 and their expected effects on functionality of   
M. avium DHFR................................................................................................. 15 
Table 4: Mutations of L32 and their expected effects on functionality of   
M. avium DHFR................................................................................................. 18 
Table 5. Restriction endonuclease reaction setup for excising the folA gene  
from the p807 plasmid construction .................................................................. 22 
Table 6. M. avium folA D31 and L32 mutants and primers used to construct them. ....... 27 
Table 7. Reaction set up for electro transformation of MG1655folA::kan3 cells with 
plasmid DNA of the recombinant wild type and mutant M. avium DHFR. ...... 44 
Table 8. Semi-automated purification of recombinant wild type DHFR on His-Bind  
resin (Novagen) with a linear gradient of 5-500 mM imidazol ......................... 52 
Table 9.Comparison of enzyme specific activity (µmole min-1 mg-1) of D31 mutated 
(D31A, D31E, D31Q, D31N, D31L) and control mutant (V76A) DHFR to  
that of the recombinant wild type (p807) at pH 7.0 and 30°C using the  
ANOVA and Dunnett procedures in the SAS statistical software  
(SAS system for Windows V8, SAS Inst. Inc, NC, USA) Dunnett  
significance level α = 0.05 ................................................................................. 54 
Table 10.Multiple comparison of enzyme specific activity (µmole min-1 mg-1) of 
recombinant wild type (p807) and D31mutated (D31A, D31E, D31Q,  
D31N, D31L) as well as control (V76A) DHFR at pH 7.0 and 30°C using  
the ANOVA and TUKEY procedures in the SAS statistical software (SAS 
system for Windows V8, SAS Inst. Inc, NC, USA) . TUKEY significance  
level α = 0.05. .................................................................................................... 55 
Table 11:Kinetic parameters at pH 7.0 and 30°C of recombinant wild type and 
D31mutants of M. avium DHFR for FAH2 and NADPH determined with  
the non-linear Michaelis-Menten curve fitting program Enzfitter  
(BioSoft, UK)..................................................................................................... 58 
Table 12. Comparison of enzyme specific activity (µmole min-1mg-1) of L32  
mutated (L32F, L32A, L32D ) DHFR to that of the recombinant wild  
type (p807) at pH 7.0 and 30°C using the ANOVA and Dunnett procedures  
in the SAS statistical software (SAS)system for Windows V8, SAS Inst.  
Inc, NC, USA) Dunnett significance level α = 0.05 .......................................... 62 
Table 13.Multiple comparison of enzyme specific activity (µmole min-1mg-1) of 
recombinant wild type (p807) and mutated (L32F, L32A, L32D) M. avium 
DHFR at pH 7.0 and 30°C using the ANOVA and TUKEY procedure in the 
vii 
SAS statistical software (SAS system for Windows V8, SAS Inst. Inc,  
NC, USA). (TUKEY significance level alpha=0.05). ....................................... 63 
Table 14.Kinetic parameters at pH 7.0 and 30°C of recombinant wild type and  
L32 mutants of M. avium DHFR for FAH2 and NADPH determined  
with the non-linear Michaelis-Menten curve fitting program Enzfitter  
(BioSoft, UK)..................................................................................................... 65 
Table 15. IC50 of trimethoprim (TMP) and SRI compounds 8858 and 20730 for 
recombinant wild type and leucine 32 mutant M. avium DHFR as  
determined by the 4 parameter curve procedure (the Bio-TEK enzyme 
software). ........................................................................................................... 70 
Table 16. Estimated relative amounts of secondary structural components of  
recombinant wild type M. avium DHFR and and D31 and L32 mutants.  
The fractions of the different structural components were calculated from  
the data shown in Figure 7 using the program Selcon3. .................................... 70 
 
viii 
LIST OF FIGURES 
Figure 1.Tetrahydrofolate biosynthesis and its role in cell metabolism.  
Enzymes for each step are given with their EC numbers.   
Examples of common antifolates that inhibit dihydrofolate  
reductase are given in box above reaction formula. ............................................ 2 
Figure 2. Chemical structures of the natural substrate folate of DHFR  
as well as the folate like inhibitors trimethoprim and methotrexate.................... 3 
Figure 3. Chemical structure of 2,4-diamino-5-methyl-5-deazapteridines  
that have been shown to be effective against M. avium (58, 59). ........................ 3 
Figure 4. Multiple sequence alignment of  M. avium DHFR with other  
prokaryotes (truncated). Sequences from GenBank. Accession numbers in 
brackets. S. epidermidis (Z48233), S. aureus (Y07536),  H. influenzae 
(X84207), B. subtilis (L77246), B. anthracis Sterne, (AAT40581) L. lactis 
(X60681), E. coli (Z50802), M. avium (AF006616), L. casei (M10922). 
(Source: (69). ....................................................................................................... 7 
Figure 5. Mycobacterium avium DHFR (EC 1.5.1.3) partial sequence of  
recombinant wild type p807 aligned with mutations at position D31 ............... 13 
Figure 6. Mycobacterium avium DHFR (EC 1.5.1.3) partial sequence of  
recombinant wild type p807 aligned with mutations at position L32................ 17 
Figure 7:Far-UV CD spectra of recombinant wild type and mutant  
M. avium DHFR. Spectra were acquired in 20mM sodium phosphate,  
100mM NaCl, pH 7.4 and 25 °C. For clarity the spectra are represented  
in two panels. With exception of the spectrum for the L32D mutant,  
which was obtained from a single protein sample, the spectra shown  
represent the average obtained from at least two independent protein 
preparations. Protein names and corresponding symbols are indicated in  
the figure. ........................................................................................................... 49 
Figure 8:Semi-automated purification scheme of recombinant wild type DHFR on  
His-Bind resin (Novagen) with a linear gradient of 5-500 mM imidazol.......... 50 
Figure 9:Determination of Michaelis-Menten parameters Km(FAH2) and  
Vmax(FAH2) of recombinant wild type M. avium DHFR (p807) at  
pH 7.0 and 30°C using the non-linear curve fit program Enzfitter  
(Biosoft, UK). Reaction was initiated by addition of enzyme after the  
substrates dihydrofolate and NADPH were incubated at 30°C for 1 minute. 
Absorbance was measured at 340 nm for minute in a Spectronic Genesis 5 
spectrophotometer in kinetic mode with 10 second reading intervals. .............. 57 
ix 
Figure 10:Growth curve at 37°C and 225 rpm of DHFR-deficient E. coli strain 
MG1655folA::kan3 transformed with recombinant wild type M. avium  
DHFR (p807), D31 mutants and the controls (V76A and pET15b vector  
only). Growth in the presence of thymidine (A) and growth in the  
absence of thymidine (B)................................................................................... 60 
Figure 11:Growth curve at 37°C and 225 rpm of DHFR-deficient E. coli strain 
MG1655folA::kan3 transformed with recombinant wild type M. avium  
DHFR (p807), L32F mutant and control pET15b vector only. Growth in  
the presence of thymidine (A) and growth in the absence of thymidine (B). .... 67 
Figure 12: Four parameter curves for determination of IC50 relative concentrations  
of SRI compound 8858 for recombinant wild type, L32D and L32A mutants of  
M. avium DHFR................................................................................................. 69 
 
 
x 
CHAPTER I 
INTRODUCTION 
Background 
Dihydrofolate reductase (DHFR, EC 1.5.1.3) is an enzyme found in both prokaryotes and 
eukaryotes and is essential in the folate biosynthetic pathway (64).  DHFR catalyzes the 
NADPH dependent reduction of dihydrofolate (H2F) to tetrahydrofolate (H4F) (Figure 1). 
The reduction of H2F to H4F is a universal requirement for the maintenance of an 
intracellular reduced folate pool (Figure 1)(24, 41). Intracellular reduced folates are 
important in one-carbon transfer reactions necessary for the biosynthesis of DNA, RNA 
and protein (Figure 1) (41). 
Due to this important role, DHFR has long been an important therapeutic drug target in 
anticancer (9), antibacterial (9) and antimalarial (52) treatment. Substrate analogues with 
high binding affinities exhibit effective inhibition that results in the depletion of the pool 
of reduced folates (41).  
Various antifolate inhibitors for DHFR have been used in the past.  Methotrexate is a 
potent inhibitor of most DHFRs and its inhibitory action is based upon its structural 
similarity to folate (Figure 2).  Trimethoprim is an effective inhibitor of bacterial DHFRs, 
but is not effective against human DHFR; its structure is also similar to dihydrofolate 
(Figure 2).  Another example of effective antifolates is the class of compounds generally 
referred to as deazapteridines.  Examples of some of these inhibitors (e.g., 2,4-diamino-5-
1 
methyl-5-deazapteridines) that have been shown to be effective against Mycobacterium 
avium are shown in Figure 3.  
 
Figure 1.Tetrahydrofolate biosynthesis and its role in cell metabolism. Enzymes for each 
step are given with their EC numbers.  Examples of common antifolates that 
inhibit dihydrofolate reductase are given in box above reaction formula.  
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Figure 2. Chemical structures of the natural substrate folate of DHFR as well as the folate 
like inhibitors trimethoprim and methotrexate 
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SRI 8858: R2 and R5 are -OCH2CH3  
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Figure 3. Chemical structure of 2,4-diamino-5-methyl-5-deazapteridines that have been 
shown to be effective against M. avium (58, 59). 
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Table 1. IC50 for trimethoprim for DHFR of various organisms. 
Organisms IC50 (nM) Reference 
Escherichia coli 7 (46) 
Staphylococcus aureus 5 (46) 
Mycobacterium avium 4100 (56, 57) 
Chicken 470000 (46) 
Mouse 280000 (46) 
Human 490000 (46) 
 
 
As stated above, trimethoprim is an effective antibacterial agent.  This drug is effective 
primarily because of its selective action against various bacterial DHFRs as opposed to 
eukaryotic DHFRs (Table 1)(27). 
Mycobacterium avium has become a serious opportunistic pathogen that causes 
significant systemic infection in persons infected with HIV (20, 23, 28, 49). Although 
trimethoprim is an effective therapy for some bacteria, it has poor activity against 
mycobacteria, including Mycobacterium avium (15, 58).  
This general resistance of  M. avium and other mycobacteria to trimethoprim and other 
antituberculous drugs coupled with the emergence of multidrug resistant clinical isolates 
of M. tuberculosis (20, 55) is evidence for the urgent need for new antimycobacterial 
4 
drugs. The development of new antifolates, particularly against mycobacteria, has 
therefore revived interest in DHFR as a drug target (15, 32, 35, 36, 42, 58, 59). 
Mycobacterium avium DHFR gene (folA) has previously been cloned and sequenced and 
submitted to GenBank under accession number AF006616 (69). It has an open reading 
frame of 543 bp and a MW of 20kDa. Mycobacterium avium DHFR amino acid sequence 
differs from M. tuberculosis and other bacteria in the sense that it has a C-terminal tail of 
13 residues with no counterparts in M. tuberculosis or other bacteria (33).  There is 
currently no published X-ray crystal structure of the M. avium DHFR, however, Kharkar 
et al. (33) have published an homology model of M. avium DHFR that was constructed 
/computed on the basis of M. tuberculosis  DHFR, using modified Needleman and 
Wunsch methodology and assessment of stereochemistry by a Ramachandran plot as well 
as with existing experimental data.   
The overall primary sequence identity among DHFR of different organisms may vary 
greatly as indicated in Table 2 and may even be as low as 17 – 20% (35). The overall 
primary structure identity of DHFR in eukaryotes and prokaryotes are usually around or 
less than 25% (61). Primary structure identities among vertebrates are usually high (65). 
The primary sequence identity of human with mouse, chicken and bovine DHFR is 89, 74 
and 81%, respectively. (37).  Compared to M. tuberculosis and E. coli the primary 
sequence identity of human DHFR is only 26 and 28%, respectively. Even among 
bacteria DHFR sequence identities can be very low. Escherichia coli and Lactobacillus 
casei DHFR have only about 28% primary sequence identity (34). On the other hand M. 
avium and M. tuberculosis have around 70% primary sequence identity. Despite such 
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large variation in primary sequence homologies, the tertiary structure of E. coli and L. 
casei DHFR is remarkably similar (34) .  
 
Table 2. Comparison of overall amino acid sequence identity in DHFR of various 
species. 
DHFR species compared % overall identity Reference 
M. avium M. tuberculosis ~70 (33) 
M. avium M. leprae 62 (69) 
M. tuberculosis Human 26 (35) 
E. coli L. casei 29 (8) 
Human E. coli 28 (53) 
Human Mouse 89 (37) 
 
All known DHFRs have the same structural features, consisting of a dominant central ß-
sheet with 4 flanking α-helices (35, 39). Major structural differences occur mostly on the 
exterior (35). Mycobacterium avium DHFR as revealed in the model of Kharkar et al. 
(33) show the same structural features, common to all other DHFRs. 
Although, as indicated in Table 2, the overall sequence identity between M. tuberculosis 
and human DHFR is only 26%, the sequence identity in the binding cavity is 55% (35). 
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Escherichia coli and L. casei also only have 28% primary sequence identity; however, 
this increases to 50% in the binding cavity (65). 
Multiple sequence alignments of all known DHFRs show very strong conserved amino 
acid residues for both vertebrates and bacteria. Figure 4 below shows a part of the amino 
acid sequence alignment of M. avium DHFR with several other bacterial species with a 
conserved aspartic acid in position 31 of M. avium. Aspartic acid 31 (D31) of M. avium is 
conserved in this position for all known bacterial DHFRs; it is replaced by glutamic acid 
in the same structural position in vertebrate DHFRs (64).  The structurally equivalent 
position of M. avium D31 is D27 in E. coli, D26 in L. casei and E30 in human DHFR.  
DHFR in vertebrates has a conserved aromatic residue (tyrosine or phenylalanine) at 
position 31 (F31 in humans), while a leucine residue is found in the same structural 
position in bacteria (L28 in E. coli, L27 in L. casei and L32 in M. avium)  (47, 69). 
 
 
Figure 4. Multiple sequence alignment of  M. avium DHFR with other prokaryotes 
(truncated). Sequences from GenBank. Accession numbers in brackets. S. 
epidermidis (Z48233), S. aureus (Y07536),  H. influenzae (X84207), B. subtilis 
(L77246), B. anthracis Sterne, (AAT40581)  L. lactis (X60681), E. coli 
(Z50802), M. avium (AF006616), L. casei (M10922). (Source: (69). 
 
 
Both of these conserved residues are in the DHFR binding cavity. The DHFR binding 
cavity is located in a very hydrophobic pocket. The highly conserved carboxylic acid 
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(D31 in M. avium, D27 in E. coli, D26 in L. casei and E30 in humans) is the only 
ionizable residue in the active site of all known DHFRs (13, 38, 45, 46). The conserved 
phenylalanine (F31 in human DHFR) or leucine (L32 in M. avium) residues together with 
other hydrophobic residues in the binding cavity are thought to ensure and maintain an 
efficient hydrophobic environment which is necessary for hydrophobic interactions with 
both the substrate and inhibitors (46). 
Changes in the conserved carboxylic acid have been shown to significantly decrease 
catalytic activity (1, 3, 11, 22, 30, 34, 40, 44, 46, 60, 64). Replacement of the aromatic 
residues have also been shown to weaken the hydrophobic interactions (14, 21, 29, 46, 
47, 63). 
The conserved aspartic acid (D27 in E. coli) was observed by Matthews et al. (39) and 
they were first to suggest that this aspartic acid must play a role in catalysis. Matthews et 
al. (38) published an X-ray crystal structure of L. casei DHFR and proposed that D27 of 
E. coli serves as proton donor in the enzyme reaction. Since then mutational studies of 
this conserved carboxylic acid residue have been done for several species and the 
importance of this residue confirmed (1, 3, 11, 22, 30, 34, 40, 44, 46, 60, 64).  
Mathews et al. (38, 39) published X-ray crystal structures of E. coli and L. casei 
complexed with methotrexate (MTX).  They showed that in both cases the p-
aminobenzoyl portion of the drug was in a hydrophobic pocket of the active site and also 
identified a number of residues that are involved in the binding of this drug. Leucine 27 
(L. casei) and leucine 28 (E. coli) were among the side chains making contact with the 
pteridine ring of methotrexate. 
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Baccanari et al. (4) reported on 2 DHFR isozymes isolated from a trimethoprim resistant 
E. coli and showed that the only difference between them was a single amino acid 
substitution.  Form 1 had a leucine residue in position 28 (L28), while Form 2 had an 
arginine (R28).  Both forms were very different in their binding and kinetic properties. 
Trimethoprim was shown to be a better inhibitor of Form 1. 
Dale et al. (16) also reported a single active site amino acid substitution in 
Staphylococcus aureus DHFR that resulted in resistance to trimethoprim.  A common 
mutation in trimethoprim resistant clinical isolates of S. aureus from diverse geographical 
regions was a substitution of phenylalanine 98 to tyrosine (F98Y). Several studies  (17, 
51) have identified 2 plasmids in staphylococci that carried trimethoprim-resistant DHFR 
genes with a single difference, namely a tyrosine in position 98.  Dale et al. (16) then 
isolated chromosomal DNA of S. aureus DHFR and introduced the same F98Y mutation 
through site-directed mutagenesis.  They found these mutants to be resistant to 
trimethoprim.  In conclusion they could show in the X-ray crystal structure that the 
tyrosine in position 98 interferes with the hydrogen bonding of leucine 5 and 
phenylalanine 92; these residues are in close contact with and bind to the inhibitor.  
Numerous studies then investigated hydrophobic interactions within the binding site of 
DHFR and through site-directed mutagenesis and X-ray crystallography identified 
functional roles of specific residues  (14, 44, 47, 48, 63). The overall conclusion from 
these studies was that there were 4 key residues that ensured efficient hydrophobic 
interaction with inhibitors.  One of those residues was L28 in E. coli and L27 in L. casei 
(46). 
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The tyrosine 98-dependent mechanism of resistance against trimethoprim that was 
described earlier (16) shows that detailed knowledge at molecular and structural level of 
resistance mechanisms could be useful in rational design of inhibitors that could be 
effective against resistant DHFRs. 
Wyss et al. (67) reported novel 2,4-diaminopyrimidines with high activity against 
trimethoprim-sensitive and trimethoprim-resistant Streptococcus pneumoniae DHFR.  
They also showed that introduction of methoxy substitutents on the drug led to 
enhancement of inhibitory activity compared to non-substituted compounds.  They 
further found that selection of compounds from structure-based libraries led to 
significantly more hits and those hits were significantly more potent than libraries based 
on diversity. 
Mycobacterium  avium is inherently resistant to trimethoprim other antibiotics and a 
variety of antimycobacterial agents (43, 49).  However, trimethoprim is differently 
selective for bacterial DHFR over mammalian DHFR (27).  Although overall tertiary 
structure for all known DHFRs are very similar, sufficient differences exist between 
species within the binding site that could be exploited to design inhibitors that are more 
selective (14). 
Suling et al. (58, 59) reported on antimycobacterial activity of 2,4-diamino-5-methyl-5-
deazapteridine derivatives (DMDPs).  In the first study, 4 of the 12 compounds showed 
selective activity against Mycobacterium tuberculosis and Mycobacterium avium, 
compared to vero cell toxicity. In the second study 77 compounds with key modifications 
investigated the binding and selectivity for M. avium DHFR compared to human DHFR.  
Although these compounds showed good activity against M. avium DHFR, they 
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concluded that compared to results reported for trimethoprim it would be necessary to 
further improve the selectivity ratio at least 10-fold so that the drugs could compare to the 
selectivity ratios of trimethoprim of other bacteria.  
Although there is currently no published crystal structure of M. avium DHFR, the model 
of M. avium DHFR that was constructed /computed on the basis of M. tuberculosis  
DHFR by Kharkar et al. (33) also identified structurally and functionally important 
residues, particularly those important for binding of the previously reported 
deazapteridine inhibitors (58, 59). Site-directed mutagenesis studies of those residues 
could further verify the importance of specific amino acid residues in the binding and 
catalysis.   
Leucine 32 in M. avium DHFR was identified as one of the residues that interact with the 
aminopteridine ring, the p-aminobenzoyl ring and the glutamate moiety of methotrexate 
(33.). This is consistent with current knowledge as reviewed above, since leucine 32 of 
M. avium is the structurally equivalent position of L28 in E. coli and L27 in L. casei (46). 
Objectives 
Based therefore on the above review of literature and crystallographic data of known 
DHFRs, as well as the proposed homology model of M. avium DHFR by Kharkar et al. 
(33.), this study hypothesizes (1) a functional role for aspartic acid 31 (D31) in the 
binding of the natural substrate and (2) a functional role for leucine 32 (L32) in the 
binding of antifolates such as trimethoprim as well as the 2,4-diamino-5-deazapteridines 
deazapteridines described previously for Mycobacterium avium DHFR .  
Hypothesis 1 
In order to test hypothesis 1, D31 of the recombinant wild type M. avium DHFR 
was substituted by alanine (D31A), glutamic acid (D31E), glutamine (D31Q), 
11 
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asparagine (D31N) and leucine (D31L) using site-directed mutagenesis (Figure 
5).  The recombinant and mutant enzymes were then expressed in E. coli and 
purified and the functionality of the mutants determined in comparison to the 
recombinant wild type in the procedures described in the materials and methods 
section of this study. Table 3 summarizes the expected effects of the D31 
mutations on the mutant enzyme’s functionality. 
Previous experiments have shown that aspartic acid 27 in E. coli (conserved 
carboxylic acid among known bacterial DHFRs) participates in proton transfer 
between solution and substrate (30, 57, 66). Changing aspartic acid 31 (D31) in 
M. avium DHFR to glutamic acid (D31E) will retain the nature of this charge, 
however, the side chain has an additional methylene group, extending the side 
chain by approximately 1 Å. If there is flexibility in terms of geometry within the 
binding cavity, then this mutation should not have an effect on the enzyme-
substrate binding and therefore should not affect the enzyme activity. 
Substituting aspartic acid 31 with glutamine (D31Q) will result in a similar 
geometry as glutamic acid (D31E), but without the carboxylic acid group. With 
the importance of the carboxylic acid group in proton transfers, this mutation 
(D31Q) should render the DHFR inactive.  
Mutating D31 to alanine (D31A) will eliminate the carboxylic acid group 
completely and remove the potential proton source. This should affect the enzyme 
activity negatively.
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Figure 5 Mycobacterium avium DHFR (EC 1.5.1.3) partial sequence of recombinant wild type p807 aligned with 
mutations at position D31 
 Asp (D) Asn (N) Leu (L) Ala (A) Glu (E) Gln (Q) 
Substituting aspartic acid 31 with asparagine (D31N) will retain the size and geometry, 
but will remove the negative charge of the carboxylic acid group. The residue will, 
however, be polar. Since aspartic and glutamic acid are the only 2 amino acids with 
negative carboxylic side groups and aspartic acid is highly conserved in this position, it is 
expected that this mutation will also render the resulting enzyme inactive. 
Changing D31 to leucine (D31L) will also retain the same size and geometry, but will 
result in a non polar side chain. This recombinant mutant M. avium DHFR is also 
expected to be dysfunctional. 
It is necessary to perform a negative control, i.e. construct a recombinant mutant M. 
avium DHFR with the same technique, with a mutation that should not have any effect on 
the enzyme’s activity. This will verify that the loss in enzyme activity is a result of the 
affected mutations and not of some side effect of the procedure. For this, Valine 76 will 
be modified to alanine (V76A). Valine 76 is sufficiently far away from the enzyme’s 
binding site and is exposed on a surface loop with no interaction with other secondary 
structural elements. 
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Table 3.Mutations of D31 and their expected effects on functionality of  M. avium DHFR 
Mutation Change in side group Hypothesis 
D31E Larger, but same charge If flexibility allowed in active site, 
no effect expected in activity 
D31Q 
 
Larger, no charge, but polar COOH group important, therefore 
enzyme dysfunctional 
D31A Smaller, no charge COOH eliminated, enzyme 
dysfunctional 
D31N Same size and geometry, remove 
negative charge, remain polar 
dysfunctional enzyme 
D31L Same size and geometry, no charge, 
nonpolar 
dysfunctional enzyme 
 
V76A “negative control” No effect on  activity 
 
Hypothesis 2  
Hypothesis 2 was tested similarly by modifying L32 of the recombinant wild type 
M. avium DHFR by site-directed mutagenesis to phenylalanine (L32F), alanine 
(L32A) and aspartic acid (L32D) (Figure 6) and assessing both the functionality 
of the enzyme as well as its interaction with trimethoprim and selected 
deazapteridine inhibitors in the procedures described in the following chapter of 
this study. The expected effects of the L32 mutations of the functionality of the 
mutant enzyme are summarized in Table 4. 
The equivalent position of M. avium leucine 32 in human DHFR is phenylalanine 
31 (F31). Changing leucine 32 in M. avium DHFR to phenylalanine (L32F) would 
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not change the hydrophobic nature, but increase the size of the side chain. If F31 
in humans contributes to trimethoprim resistance, this mutation should decrease 
selectivity of the mutant for trimethoprim. 
Given the proposed role of leucine 32 in interacting with inhibitors, the L31A 
mutations would remove this important hydrophobic side chain and lessen the 
affinity of the inhibitor, thereby also decreasing selectivity. 
The L32D mutation will not only remove the hydrophobic side chain of the wild 
type, but also introduce a charged group into an overall hydrophobic region. It is 
expected that the loss of hydrophobicity will negatively affect inhibitor binding 
and decrease selectivity. 
Figure 6 Mycobacterium avium DHFR (EC 1.5.1.3) partial sequence of recombinant wild type p807 aligned with 
mutations at position L32  
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 Leu (L) Asp (D) Ala (A) Phe (F) 
Table 4: Mutations of L32 and their expected effects on functionality of  M. avium DHFR 
Mutation Change in side group Hypothesis 
L32F Larger, but still hydrophobic No effect on enzyme activity expected 
Effect on inhibitor IC50 expected 
 
L32A 
 
Smaller, no charge, 
remove hydrophobic residue 
 
No effect on enzyme activity or inhibitor 
selectivity expected 
 
L32D 
 
Same size, remove 
hydrophobicity, introduce charge
No effect on enzyme activity expected 
Effect on inhibitor IC50 expected 
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CHAPTER 2 
MATERIALS AND METHODS 
Bacterial strains used 
E. coli JM109 (Promega) 
E. coli BL21(DE3)pLysS (Promega) 
E. coli BMH71-18mutS (Promega) 
E. coli MG1655 
E. coli MG1655folA::kan3 
Mycobacterium avium DHFR gene (folA) 
Mycobacterium avium folA gene has first been identified, cloned and sequenced and 
submitted to GenBank under accession number AF006616 (69). It has an open reading 
frame of 543 bp and a MW of 20kDa.  Functionality of the recombinant enzyme was 
shown in vitro in a standard enzyme assay as well as in vivo through functional 
complementation (69) . 
Plasmid vector construct p807 for recombinant M. avium DHFR 
Plasmid DNA of the previously cloned M. avium folA gene was available in the Lab of 
Dr. W. Barrow. The M. avium folA gene had previously been cloned into the pET15b 
vector (Novagen) at the Nde1 and BamH1 restriction sites. (69).  The pET15b vector 
contained an N-terminal His-tagged leader sequence.  
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This plasmid construct consisting of the pET15b vector with the M. avium folA gene 
insert, will serve as the recombinant wild type M. avium DHFR. 
Validation (Verification) of recombinant wild type M. avium DHFR 
E. coli JM109 competent cells (Promega) were transformed with recombinant wild type 
DHFR plasmid construct p807 DNA according to Promega E. coli competent cells 
Standard Transformation Protocol.  
Transformation 
Sterile polypropylene Falcon® 2059 tubes were chilled on ice. High efficiency 
competent cells (>108 cfu/µg) were thawed on ice for five minutes and 100 µl 
cells transferred to each tube. About 10 ng of plasmid DNA was added to each 
tube and the tube flicked gently. These tubes were kept on ice for 10 minutes, 
then heat-shocked for 45-50 seconds in a water bath at exactly 42°C. The reaction 
was returned to ice for two minutes and 900 µl SOC medium (Novagen) was 
added to each tube. Tubes were incubated for 60 minutes at 37°C in a shaking 
incubator at 225 rpm. For each reaction 100 µl was plated undiluted, diluted 1:10 
and 1: 100 onto Luria-Bertani (LB) Agar containing 100µg/ml carbenicillin. 
Plates were incubated at 37°C for 12 – 14 hours. 
Overnight cell growth 
A single colony was grown overnight in 10 ml LB-Broth with 100 µg/ml 
carbenicillin in a shaking incubator at 37°C and 225 rpm. Cells were harvested by 
centrifugation at maximum speed (2135 x g) at 4°C for 10 minutes (Sorval RTH-
250 rotor). 
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Plasmid DNA extraction 
Plasmid DNA was extracted using the Wizard® Plus SV miniprep DNA 
purification system (Promega). The pellet from the overnight culture was 
resuspended into 250µL cell resuspension solution and vortexed to ensure 
complete resuspension. Thereafter 250 µl cell lysis solution was added and tubes  
were mixed by inverting several times until cell suspension cleared. After five 
minutes 10 µl alkaline protease solution was added and were again mixed by 
inverting several times.  Tubes were incubated at room temperature for 5 minutes 
and 350 µl Wizard® Plus SV neutralization solution was added and tubes were 
mixed by inverting. The lysate was centrifuged in a table top microcentrifuge at 
14,000 x g for 10 minutes at room temperature. The plasmid DNA was then 
purified by microcentrifugation using Wizard® Plus SV miniprep spin columns. 
For each sample a spin column was inserted into a 2 ml collection tube. The 
supernatant of the prepared lysate was then transferred to the spin column either 
by decanting or pipetting. Care was taken not to transfer any of the precipitate. 
The columns were centrifuged at maximum speed (14,000 x g) at room 
temperature for one minute. The flow through was discarded and the spin 
columns were reinserted into the collection tubes. Columns were washed by 
adding 750 µl column wash solution onto each spin column. Columns were again 
centrifuged at maximum speed (14,000 x g) at room temperature for one minute. 
The flow through was discarded and the process repeated with 250 µl column 
wash solution, but this time centrifuged for 2 minutes. The spin columns were 
transferred to sterile 1.5 ml centrifuge tubes. To elute the plasmid DNA 100 µl 
nuclease-free water was added to the spin columns and columns were centrifuged 
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at 14000xg for 1 minute at room temperature. After determining the plasmid 
DNA concentration and purity, the plasmid DNA was stored at -20°C until further 
use. 
Determining plasmid DNA concentration and purity 
Plasmid DNA concentration was determined in a GeneQuant proRNA/DNA 
calculator (Amersham) using quartz microcapillaries. 
Restriction endonuclease digestion and agarose gel electrophoresis 
Extracted plasmid DNA was subjected to restriction endonuclease double 
digestion with BamH1 and Nde1 and agarose gel electrophoresis in order to verify 
the presence of the insert. The reaction setup is described in Table 5. The same 
plasmid DNA was also sequenced in order to confirm the insert as the DHFR 
gene. 
Table 5. Restriction endonuclease reaction setup for excising the folA gene from the p807 
plasmid construction 
 
pET15b 
undigested 
pET15b digested p807 undigested p807 digested 
Sterile dH2O 15.8 µl 15.6 µl 7.3 µl 10.5 µl 
BamH1 Buffer 2 µl 2 µl 2 µl 2 µl 
100X BSA 
(100mg/ml) 
0.2 µl 0.2 µl 0.2 µl 0.2 µl 
Template DNA 2 µl (~ 1µg) 2 µl (~ 1µg) 10 µl (1µg) 10 µl (1µg) 
BamH1 - 0.25 µl (5 U) - 0.25 µl (5 U) 
Nde1 - 0.25 µl (5 U) - 0.25 µl (5 U) 
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The 20 ml reaction tubes were incubated in a 37°C water bath for 2 hours. After 
digestion 4 ml 6X loading buffer (Promega). A 1.2% agarose gel was prepared by 
adding 30 ml 1 X TAE buffer to 0.36g agarose and heating it in a microwave until 
boiling ( about 1 minute). After cooling to about 50°C 1.5 µl ethidium bromide 
(Promega: 10mg/ml) was added to the agarose  and the gel was poured in a flat 
bed  tray 7x6.2x1 cm. Electrophoresis was carried out for 50 minutes at 75V in a 
mini-sub® cell GT electrophoresis chamber (Promega) using 1X TAE buffer.   
Sequencing 
Mutations were confirmed by sequencing the full length of the folA gene insert of 
the pET15b vector using T7 forward and reverse primers. Sequencing was done at 
either the Recombinant DNA/Protein Resource Facility of Oklahoma State 
University (Stillwater, OK) or at the Oklahoma Medical Research Foundation 
(OMRF, Oklahoma City, OK). 
Pilot expression of recombinant wild type M. avium DHFR 
Transformation 
BL21(DE3) pLysS competent cells (Promega) were transformed with 
recombinant DHFR plasmid construct p807 DNA, according to Promega E. coli 
competent cells Standard Transformation Protocol as described above (Section 
2.4.1). Each transformation reaction was plated undiluted onto LB-Agar 
containing 100 µg/ml carbenicillin and 34 µg/ml chloramphenicol and incubated 
overnight at 37°C. 
Growth and IPTG induction 
A single colony was grown overnight in 10 ml LB-Broth with 100 µg/ml 
carbenicillin and 34 µg/ml chloramphenicol in a shaking incubator at 37°C and 
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225 rpm. From each 10 ml overnight culture 500 µl was used to inoculate 10 ml 
LB-Broth containing 100 µg/ml carbenicillin and 34 µg/ml chloramphenicol. The 
culture was grown in a shaking incubator at 37°C and 225 rpm until an OD600 of 
0.6 - 0.7 was obtained. At this point the growing culture was divided into 2 x 5ml 
using sterile 50 ml conical tubes. From each culture 500 µl were removed as a 
pre-induced sample and non-induced sample at zero time. Samples were 
centrifuged at 16,000 x g for 20 minutes at 4°C; the supernatants were discarded 
and the pellets stored at -20°C until used. Only one of these cultures was induced 
by adding 1 mM IPTG (final conc.). Both cultures (induced and non-induced) 
were continued to grow at 28°C in a shaking incubator at 225 rpm for 21-24 
hours.  At this point another 500 µl was removed as induced and non-induced 
sample at time 21 or 24 hours and centrifuged as above. After 24 hours cells were 
harvested by centrifugation at 4°C at maximum speed (2135 x g) for 20 minutes 
(Sorval RTH-250 rotor).  
BugBuster protein extraction  
BugBuster Protein Extraction Reagent Kit and Benzonase nuclease (Novagen) 
and Protease Inhibitor cocktail III (Calbiochem) were used to lyse the cells and 
extract the soluble protein from the pellets.  Pellets were resuspended in 100 µl 
Bugbuster® Protein Extraction Reagent and 0.1 µl Benzonase Nuclease reagent 
and incubated on a shaker at room temperature for 15 minutes. The cell lysate was 
centrifuged at 4° at 16,000 x g for 20 minutes. The supernatant was collected and 
stored at -20°C until use in SDS-PAGE. 
24 
Polyacrylamide gel electrophoresis (SDS-PAGE) 
Samples for SDS-PAGE were prepared by adding 10 µl 2x SDS-sample buffer 
(Novagen) to 10 µl extract. Samples were heated at 95°C for 5 minutes in a 
heating block and thereafter kept on ice for at least 10 minutes before 
electrophoresis. Electrophoresis took place under denaturing conditions on a 
12.5% (w/v) polyacrylamide gel.  
Composition of gels and solutions were as follow: 
Separating gels 
Acrylamide/N’N-methylene bisacrylamide 12.5% (w/v) 
Tris-HCl, pH 8.8 375 mM 
SDS 0.1% (w/v) 
Stacking gels 
Acrylamide/N’N-methylene bisacrylamide 6.0% (w/v) 
Tris-HCl, pH 6.8 125 mM 
SDS 0.1% (w/v) 
Gels were polymerized by the addition of N,N,N’,N’,-Tetramethylene ethylene 
diamine (TEMED) and Ammonium persulphate (APS) 10%w/v as indicated 
below: 
 Separating gel  Stacking gel 
N,N,N’,N’,-Tetramethylene  
ethylene diamine (TEMED)  0.1% (v/v) 0.1% (v/v) 
Ammonium Persulphate (APS) 10%w/v 0.1% (v/v) 0.1% (v/v) 
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SDS sample buffer 
125mM Tris-HCl, pH 6.8, 
2.0% (w/v) SDS 
20% (w/v) glycerol 
0.001% (w/v) Bromophenol blue 
0.05% (w/v) ß-mercaptoethanol 
Electrophoresis running buffer 
25 mM Tris-Hcl, pH 8.3 
192 mM Glycine 
0.1% (w/v) SDS 
 
Gels were run for 45 minutes at 200 Volts constant and then stained for several 
hours or over night in Coomassie blue R-250 solution [0.1% (w/v) Coomassie 
blue R-250, 50% (v/v) methanol, 10% (v/v) acetic acid]. 
The gels were destained for several hours until the gels had a clear and transparent 
background (Destain solution: 40% (v/v) methanol and 10% (v/v) acetic acid).  
Site-directed mutagenesis 
The p807 plasmid construct of the M. avium folA gene was used as template DNA for 
oligonucleotide-based site-directed mutagenesis of aspartic acid 31 (D31) and leucine 32 
(L32) as well as the control mutation valine 76 (V76), using the GeneEditor Protocol Kit 
(Promega).  
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Design and synthesis of mutagenic oligonucleotides 
Mutagenic oligonucleotides were designed in accordance with Promega’s 
GeneEditor Kit recommendations (Promega TM 047). Single base changes should 
have about 17 – 20 bases with about 8 – 10 matched bases on either side. For 2 or 
more mismatches, oligonucleotides of 25 or longer bases are required with about 
12 – 15 matched bases on either side.  The mismatch should be as close to the 
center as possible. The following mutagenic oligonucleotides were commercially 
synthesized and PAGE purified (IDT) (Table 6).   
 
Table 6. M. avium folA D31 and L32 mutants and primers used to construct them. 
Mutation Primers, 5’-3’, with mutational codon highlighted in bold 
D31E  
D31Q 
D31A 
D31N 
D31L 
V76A 
L32F  
L32A 
 
L32D 
CGAGGAGCTCACCCGGTTCAAG 
CGTGCCCGAGCAACTCACCCGGTTC 
CGAGGCCCTCACCCGGTTCAAAG 
GCCCGAGAACCTCACCCGGTTCAAAG 
CGTGCCCGAGCTCCTCACCCGGTTCAAAG 
CCCGACTTCGCCGCCGAGGGG 
GCCCGAGGACTTCACCCGGTTC 
GCCCGAGGACGCCACCCGGTTC 
GCCCGAGGACGACACCCGGTTC 
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 5’-Phosphorylation of mutagenic oligonucleotides 
All mutagenic oligonucleotides were 5’-phosphorylated prior to the mutagenesis 
procedure. The reaction set up and procedure were as follow: 
Mutagenic oligonucleotide 100pmol 0.5µl 
Kinase 10X Buffer  2.5µl 
T4 Polynucleotide Kinase 5U 0.5µl 
ATP, 10mM  2.5µl 
Sterile deionized H2O to final volume of  25µl 
The reaction was incubated in a water bath at 37°C for 30 minutes and then 
heated to 70°C in a heating block for 10 minutes in order to inactivate the T4 
Polynucleotide kinase. The reaction product was stored at -20°C until used. 
Mutagenesis reaction 
Alkaline denaturation (dsDNA) 
The recombinant wild type plasmid DNA (p807) was used as a template to 
generate all the mutants. GeneEditor control DNA (pGEM11z(f) vector) was also 
denatured during the same procedure. Non-denatured controls did not contain the 
2M NaOH, 2mM EDTA, but were otherwise treated in the same manner. The 
remaining volume was made up with sterile deionized H2O. The following 
reaction setup generated enough denatured DNA for 10 mutagenesis reactions: 
dsDNA template    0.5pmol (approx. 2µg) 
2M NaOH, 2mM EDTA   2µl 
sterile deionized H2O to final Volume 20µl 
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The reaction was incubated at room temperature for 5 minutes, and then 2µl of 
2M ammonium acetate (pH4.6) and 75µl of 100% cold (4°C) ethanol were added. 
The reaction was further incubated at -70°C for 30 minutes. The reaction was 
centrifuged at 16,000 x g in a micro centrifuge for 15 minutes at 4°C. The pellets 
were drained and washed with 200µl of 70% ethanol (4°C) and centrifuged as 
above. The pellets were dried under vacuum in a speedvac for 30 minutes with 10 
minutes heating time at medium level.  Pellets were suspended in 100 µl TE 
buffer (pH 8.0) and a 10 µl sample was analysed for denaturation on an agarose 
gel before the next step in the procedure. 
Agarose gel electrophoresis 
A 0.8% agarose gel was prepared by adding 30 ml 1 X TAE buffer to 0.24g 
agarose and heating it in a microwave until boiling (about 1 minute). After 
cooling to about 50°C, 1.5 µl ethidium bromide (Promega: 10mg/ml) was added 
to the agarose  and the gel was poured in a flat bed  tray 7x6.2x1 cm. 
Electrophoresis was carried out for 50 minutes at 75V in a mini-sub® cell GT 
electrophoresis chamber (Promega) using 1X TAE buffer 
Oligonucleotide hybridization 
The GeneEditor™ mutagenesis system is supplied with two selection 
oligonucleotides: Top- and Bottom Strand. The Top Strand is identical in 
sequence to the mRNA that encodes for the ampicillin resistance (ß-lactamase 
gene) which is carried as a selection marker on the plasmid vector. Both the 
mutagenic and the selection oligonucleotide have to hybridize to the same strand. 
The orientation of the inserted gene and the ampicillin resistance gene of the 
vector determine which of the two selection oligonucleotides to use. The folA 
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insert in the pET15b vector and the ampicillin resistance gene in that plasmid 
vector both had the same orientation, so the selection oligonucleotide Top Strand 
was used. 
 
For each mutation a separate reaction was set up in an eppendorf tube as indicated 
below: 
 
Alkaline denatured Template DNA 0.05pmol 10µl 
Selection oligonucleotide Top Strand 
(phosphorylated, 2.9ng/µl) 0.25pmol   1µl 
mutagenic oligonucleotide 
(Phosphorylated) 1.25pmol 0.31µl 
Annealing 10X Buffer  2.0µl 
Sterile deionized H2O to final volumes of  20µl 
 
The mutagenesis control reaction utilizes an oligonucleotide that disrupts the lacZ 
α-peptide of the control vector (pGEM®-11Zf(+)). E. coli JM109 that is 
transformed with transformants carrying the control mutation will form white 
colonies on agar media containing X-Gal and IPTG. The reaction set up for the 
mutagenesis control reaction was as follows: 
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Alkaline denatured pGEM®-11Zf(+) vector DNA 0.05pmol 10µl 
Selection oligonucleotide, Bottom Strand 
 (phosphorylated, 2.9ng/µl)   0.25pmol   1µl 
lacZ Control Knockout oligonucleotide 
 Bottom strand (13.2ng/µl)   1.25pmol   1µl 
Annealing 10X Buffer    2.0µl 
Sterile deionized H2O to final volumes of  20µl 
The hybridization reactions were heated to 75°C for 5 minutes in a water bath and 
then allowed to cool down to 37°C at a rate of about 1.5°C per minutes. This was 
achieved by removing about 200 ml of water from the water bath with a beaker, 
and keeping the reaction tubes in the beaker at room temperature for about 30 – 
40 minutes. 
Mutant strand synthesis and ligation 
Once the annealing reaction had cooled down to 37°C, tubes were centrifuged 
briefly to collect the contents at the bottom of the tube. In order to complete the 
strand synthesis (heteroduplex formation), the following components were added 
to the reaction tubes in the order listed: 
Sterile deionized H2O  5µl 
Synthesis 10X Buffer  3µl 
T4 DNA Polymerase 5U 1µl 
T4 DNA Ligase 1-3U 1µl 
Final volume  30µl 
These reactions were incubated at 37°C for 90 minutes in a water bath and then 
kept on ice. 
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Transformation of BMH 71-18 mutS (repair-minus strain) 
Transformation and over night growth 
Sterile polypropylene Falcon® 2059 tubes were chilled on ice. BMH 71-
18 mutS competent cells (>107 cfu/µg) were thawed on ice or five minutes 
and 100 µl cells transferred to each tube. About 10 ng of template DNA 
(1.5µl of each mutagenesis reaction) was added to each tube respectively 
and the tube flicked gently. These tubes were kept on ice for 10 minutes, 
then heat-shocked for 45-50 seconds in a water bath at exactly 42°C. The 
reaction was returned to ice for two minutes and 900 µl room temperature 
LB broth without antibiotic was added to each tube. Tubes were incubated 
for 60 minutes at 37°C in a shaking incubator at 225 rpm. For each 
reaction an overnight culture was prepared by adding 4ml LB medium 
containing 100 µl of the GeneEditor™ Antibiotic Selection Mix to each 
transformation reaction. Reactions were incubated for 16 – 18 hours in a 
shaking incubator (225rpm) at 37°C.  
Plasmid DNA extraction 
Plasmid DNA was extracted from the BMH 71-18 mutS overnight cultures 
as described above.  
Determination of plasmid DNA concentration and purity 
Plasmid DNA concentration was determined in a GeneQuant 
proRNA/DNA calculator (Amersham) using quartz microcapillaries. 
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Transformation of JM109  
Transformation  
Sterile polypropylene Falcon® 2059 tubes were chilled on ice. High 
efficiency competent cells (>108 cfu/µg) were thawed on ice or five 
minutes and 100 µl cells transferred to each tube. For each mutation about 
10 ng of plasmid DNA extracted from the BMH 71-18 mutS cells was 
added to each Falcon® 2059 tube and the tube flicked gently. These tubes 
were kept on ice for 30 minutes, then heat-shocked for 45-50 seconds in a 
water bath at exactly 42°C. The reaction was returned to ice for two 
minutes and 900 µl (room temperature) SOC medium (Novagen) was 
added to each tube. Tubes were incubated for 60 minutes at 37°C in a 
shaking incubator at 225 rpm. For each reaction, 100 µl was plated 
undiluted, diluted 1:10 and 1: 100 onto LB Agar containing 125µg/ml 
carbenicillin and 100µl of the GeneEditor™ Antibiotic Selection Mix for 
20 ml LB agar.  That mixture was spread onto 20 ml agar and incubated at 
37°C for 30 minutes. Plates were incubated at 37°C for 12 – 14 hours. 
Overnight cell growth 
For each mutation at least 5 isolated colonies were selected and grown 
separately overnight in 10 ml LB-Broth with 100 µg/ml carbenicillin and 
50 µl GeneEditor™ Antibiotic Selection Mix in a shaking incubator at 
37°C and 225 rpm (12-14 hours). Cells were harvested by centrifugation 
at maximum speed (2135 x g) 4°C for 10 minutes (Sorval RTH-250 rotor).  
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Plasmid DNA extraction 
Plasmid DNA was extracted using the Wizard® Plus SV miniprep DNA 
purification system (Promega) as described above. 
Determining plasmid DNA concentration and purity 
Plasmid DNA concentration was determined in a GeneQuant 
proRNA/DNA calculator (Amersham) using quartz micro capillaries 
Sequencing 
Mutations were confirmed by sequencing the full length of the folA gene 
insert of the pET15b vector using T7 forward and reverse primers. 
Sequencing was done at either the Recombinant DNA/Protein Resource 
Facility of Oklahoma State University (Stillwater, OK) or at the Oklahoma 
Medical Research Foundation (OMRF, Oklahoma City, OK). 
Large scale protein expression of recombinant mutant DHFR  
Transformation  
High Efficiency BL21(DE3)pLysS  competent cells (Promega) were 
transformed with 10 ng plasmid DNA of successful mutants as well as 
with the recombinant wild type DHFR as described under Section  2.4.1 
above. For each transformation reaction 100 µl was plated undiluted on 
LB Agar containing 100µg/ml carbenicillin and 34µg/ml chloramphenicol.  
Plates were incubated overnight at 37°C. 
Overnight cell growth and IPTG induction 
For each mutant and the recombinant wild type a single colony was grown 
overnight in 10 ml LB-Broth with 100 µg/ml carbenicillin and 34µg/ml 
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chloramphenicol in a shaking incubator at 37°C and 225 rpm. Cells were 
then centrifuged at maximum speed (2135 x g) at 4°C for 10 minutes 
(Sorval RTH-250 rotor) and resuspended in 10 ml fresh LB-medium with 
100 µg/ml carbenicillin and 34µg/ml chloramphenicol. Each overnight 
culture was used to inoculate 500 ml LB medium containing 100 µg/ml 
carbenicillin and 34µg/ml chloramphenicol. Cultures were grown in 2 L 
flasks in a shaking incubator at 225 rpm and 37°C until an OD600 of  0.5 
– 0.7. At this point cultures were cooled down to room temperature before 
0.1 M (final conc.) IPTG was added to each culture. The cultures were 
then grown at 28°C in a shaking incubator at 225 rpm for 24 hours. Cells 
were harvested by centrifugation in pre-weighed 250 ml cups at 16 000xg 
and 4°C for 20 minutes (Beckmann JLA 16.250 rotor). After determining 
the wet weight of the pellets, pellets were stored frozen at -80°C 
overnight. 
BugBuster protein extraction  
BugBuster Protein Extraction Reagent Kit, Benzonase nuclease (Novagen) 
and Protease Inhibitor cocktail III (Calbiochem) were used to lyse the cells 
and extract the soluble protein from the pellets.  Pellets were resuspended 
in 5ml/g wet cells Bugbuster® Protein Extraction Reagent and 1 µl/ml 
Benzonase Nuclease reagent, 10 µl/ml proteinase cocktail and 2µl/ml 
lysozome (10mg/ml) and incubated on a shaker (low setting) at room 
temperature for 30 minutes. The cell lysate was centrifuged at 4° and 
16,000 x g for 20 minutes. The supernatant was collected and first filtered 
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through a 0.45µ membrane filter, then through a 0.22µ membrane filter. 
Sterile glycerol was added to 10% and the filtrate was stored at -80°C as 
PreColumn samples until used. Aliquots were taken for protein 
determination and SDS- PAGE.  
BioRAD protein determination (microassay procedure for 
microplates) 
IgG protein standards (BioRAD) were diluted to 1.37mg/ml with sterile 
deionized H2O and aliquots were kept at -80°C as stock solution. A 
working solution was prepared by diluting the stock solution tenfold to 
0.137mg/ml. Aliquots were kept at -20°C. 
For the protein assay, 550µl each of 10, 35, 50, 65 and 80µg/ml standards 
were prepared by appropriate dilution with sterile deionized H2O. Each 
standard was loaded in triplicate on a microtiter plate. 
Dilutions, varying from 1:10 – 1:3,000, were prepared with sterile 
deionized H2O for each of the cell extracts. Each of these samples was 
also loaded in triplicate in the same microtiter plate as the standards.  
Sterile deionized H2O was loaded in triplicate as an assay reagent blank. 
Into each well of the microtiter plate with protein and blank, 40µl 
BioRAD dye reagent concentrate was added. The microplate was shaken 
on a plate shaker at medium speed for 20 – 30 minutes and absorbance 
was determined at 595 nm in a microplate reader (microplate auto reader 
EL311, BIO-TEK Instruments). 
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Polyacrylamide gel electrophoresis (SDS-PAGE) 
For each extract samples were prepared and electrophoresis performed as 
described above. 
Purification of recombinant mutant and wild type DHFR (semi-automated 
procedure) 
The target protein was purified using His-Bind resin (Novagen) under non-
denaturing conditions. According to the manufacturer, 5.0 ml His-Resin slurry 
(2.5 ml settled resin) will bind about 20 mg His-tagged protein. Procedures for 
preparing the His-resin and Column were done according to Novagen Technical 
Bulletin TB054. 
His-Resin and column preparation (manual operation)  
Based on the amount of total protein in the Bugbuster extract, an 
appropriate amount of His-Resin slurry was transferred (wide mouth 
pipet) into either a 10 or 20 cm Econo- Column (Bio-RAD) with an inner 
diameter of 1.0 cm. The stop-cock at the bottom of the column was kept 
open in order to allow excess buffer to drain and the resin to pack. The 
stop-cock was closed when the buffer had reached the surface of the 
settled resin. 
i. The following sequence was used to wash charge and equilibrate 
the resin: 
ii. In order to wash out residual ethanol of the storage buffer, 3 
column volumes of sterile deionized H20 was loaded onto the 
column and allowed to drain by gravity flow. 
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iii. The Column was then charged by loading 5 column volumes of 1X 
Charge Buffer (Novagen) [1X Charge Buffer: 50 mM NiS04 ] 
(gravity flow).  iii) 3 column volumes of lX Binding Buffer [ 5 
mM imidazol, 500 mM NaCl, 20 mM Tris-HCl, pH 7.9] 
(Novagen) was used to equilibrate the resin (gravity flow). 
Loading and washing the column (manual operation)  
The recombinant protein extract was loaded with a pipette onto the 
charged resin and allowed to flow by gravity. The stop-cock at the bottom 
of the column was adjusted to allow for a flow rate of 12 drops per minute. 
The flow-through fraction was collected and saved. When all of the extract 
had passed through the column so that it reached the surface of the resin, 
the resin was washed with 10 column volumes of 1X Binding buffer that 
contained 5% glycerol (wash 1). The process was either repeated 2 more 
times (washes 2 and 3), or depending on the total amount of protein 
loaded, wash 3 was modified by increasing he amount of imidazol in the 
buffer to 40 mM. The column was then washed again with IX Binding 
Buffer. All washes were collected and saved. A 280 nm reading was taken 
of the flow-through and all the washes. Washing was continued until the 
280nm reading became negligible. 
Biologic LP chromatography system (BioRAD) 
Before elution of the HisResin bound His-tagged recombinant DHFR with 
the Biologic LP chromatography system, the instrument was prepared 
according to the manufacturer’s instructions. The lines were primed with 
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buffer A [5 mM imidazol, 500 mM NaCl, 20 mM Tris-HCl, pH 7.9] and 
Buffer B [500 mM imidazol, 500 mM NaCl, 20 mM Tris-HCl, pH 7.9] 
and the UV absorbance was zeroed. The system was also programmed for 
the elution and fractious collection steps. A BioFrac fraction collector 
(Bio-RAD) was connected to the chromatography system and was 
controlled automatically via the system’s control unit. The elution was 
monitored on a connected computer using the system’s LP Data View 
v1.01 software (Bio-RAD).    
Elution (automated procedure) 
The column was connected to the Biologic LP Chromatography System 
and the automated procedure started. The column was first washed with 
5 ml of Buffer A [5 mM imidazol, 500 mM NaCl, 20 mM Tris-HCl, pH 
7.9]]  at a flow rate of 1ml/minute. The fraction collector was set to collect 
all 5 ml as one fraction. Elution was continued as a linear gradient of 0 – 
100% Buffer B (5 - 500 mM imidazol) over a volume of 20 ml. The 
fraction collector was set to collect all with 2 ml fraction size. Elution was 
continued with an additional 20 ml of 100% Buffer B (500 mM imidazol) 
to ensure that all protein was eluted from the column. All fractions were 
collected with a fraction size of 2 ml.   
After elution was completed (UV absorbance had reached baseline), 
samples were removed and aliquoted for protein determination, SDS-
PAGE and enzyme assays. Samples for protein determination and SDS-
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PAGE were stored at -20°C while samples for enzyme assay were stored 
at -80°C. 
Functionality of recombinant mutant DHFR 
The functionality of the mutants was determined in a standard DHFR enzyme 
assay in comparison to the recombinant wild type and by their ability or inability 
to restore growth of a DHFR-deficient E. coli strain (growth complementation), 
also in comparison to the recombinant wild type. 
DHFR standard enzyme assay 
The enzyme assay for determining functionality of the DHFR mutants was 
performed as described by Zywno-van Ginkel et al. (69).The 1 ml enzyme 
reaction mixture contained 10 mM 2-mercatoethanol (Bio-RAD), 0.1 mM 
NADPH – tetrasodium salt (Sigma, St. Louis, MO), 50 mM potassium 
phosphate – 1 mM EDTA (Promega, Madison, WI), pH 7.0 and 10 µl of 
the enzyme fraction. The reaction mixture was incubated at 30ºC for 3 
minutes, after which 0.1 mM dihydrofolic acid (FAH2) (Sigma) was added 
to initiate the reaction. The activity was measured as a decrease at 340 nm 
in a Spectronic Genesis 5 spectrophotometer for 3 minutes in kinetic mode 
with 10 second reading intervals.  The enzyme fraction was appropriately 
diluted with BSA in order to achieve a linear reaction progress (progress 
curve) over the entire 3 minute period. Each enzyme sample was measured 
multiple times. The reaction was corrected for NADPH oxidation, by 
repeating the above reaction set up and incubation, but without addition of 
FAH2 for the 340 nm reading. One unit was defined as the amount of 
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enzyme which reduced 1 µmole FAH2  per minute based on a molar 
extinction coefficient of 12300 M-1cm-1 at 340 nm (26). 
Kinetic assay 
In order to determine the kinetic parameters of the wild type and mutant 
DHFR, the assay resembled the standard assay above, but with the 
following modifications:  
For FAH2,   the NADPH concentration was kept constant at 100 µM, while 
the concentration of FAH2 was varied from 5 – 0.35 µM. The 1 ml 
reaction was incubated for one minute as described above, but with the 
NADPH and the FAH2. The reaction was initiated by addition of the 
enzyme and the activity was measured as described above, but for one 
minute at 10 second reading intervals. The amount of enzyme used was 
the amount that gave a linear progress curve over the 3 minute 
measurement during the standard assay. 
For NADPH, the concentration of FAH2 was kept constant at 100 µM, 
while that of NADPH was varied from 10 – 0.7 µM. The reaction 
components were incubated as described above and the reaction was also 
enzyme initiated.  
IC50 determination 
Stock solutions for each drug were prepared at 10.24mg/ml in sterile 
DMSO (Sigma, St. Louis, MO) and stored at -20°C. For the drug assay the 
stock solution was diluted with sterile DMSO to 1.024mg/ml. This 
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working solution was used to prepare a series of drug concentrations 
ranging from 1024 µg/ml to 0.01024µg/ml. 
The assay resembled the standard enzyme assay as described above.  At 
first the standard assay was done in order to determine the amount of 
enzyme to be used throughout the assay. The 1 ml enzyme reaction 
mixture contained 10 mM 2-mercatoethanol (Bio-RAD), 50 mM 
potassium phosphate – 1 mM EDTA (Promega, Madison, WI), pH 7.0 and 
0.1 mM NADPH – tetrasodium salt (Sigma, St. Louis, MO) as well as 10 
µl of the enzyme fraction and the appropriate drug concentration 
respectively. The reaction mixture was incubated at 30ºC for 3 minutes, 
after which 0.1 mM dihydrofolic acid (FAH2) (Sigma) was added to 
initiate the reaction. The activity was measured as a decrease at 340 nm in 
a Spectronic Genesis 5 spectrophotometer for 3 minutes in kinetic mode 
with 10 second reading intervals. In order to determine the effect of 
DMSO on the reaction, the reaction set up was repeated with 10 µl of 
DMSO only, instead of the drug.  The effect of NADPH oxidation was 
taken into account as described under the standard assay. Percentage 
inhibition was calculated by determining the quotient of the activity 
obtained with the drug and that obtained in the reaction with DMSO only. 
At least 4 values were determined for each enzyme sample: 2 above the 
50% inhibition and 2 below. The concentration of the drug that inhibited 
the reaction by 50% (IC50) was computed using the 4 parameter curve 
program of the KC junior software (Bio-TEK, Winooski, VT). 
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Growth complementation 
The DHFR-deficient strain MG1655folA::kan3 as well, as its parent strain 
MG1655, (25), was available in our laboratory as frozen glycerol stocks. 
A sterile inoculation loop was used to transfer and streak out some cells 
from these frozen glycerol stocks onto LB-Agar. The LB-Agar for the 
parent strain did not contain any antibiotics, while that of the DHFR-
deficient strain contained 30 µg/ml kanamycin (GIBCO™/Invitrogen) and 
50 µg/ml thymidine (Sigma). The plates were incubated overnight at 37ºC 
(Isotemp incubator, Fischer Scientific). 
For each strain an isolated colony was selected and grown overnight in 
12.5 ml LB-medium that contained no antibiotics for the parent strain, but 
30 µg/ml kanamycin  and 50 µg/ml thymidine for the DHFR-deficient 
strain. 
The 12.5 ml overnight cultures were used to inoculate 250 ml LB-medium 
respectively that contained the same antibiotic conditions as before. The 
cultures were grown at 37ºC in a shaking incubator at 225 rpm until an 
OD600 of 0.5-1.0 (approximately 6 hours). Cells were then chilled on ice 
for 15 – 30 minutes and centrifuged at 4ºC for 15 minutes at 4,000xg. The 
pellets were suspended in 250 ml sterile H2O and re-centrifuged as above. 
These pellets were resuspended in 125 ml sterile H2O and centrifuged as 
above. 
The pellets were resuspended in 5 ml 10% glycerol. After centrifugation 
as above, the pellets were resuspended in 500 µl 10% glycerol, aliquoted 
into sterile eppendorf tubes and stored at -80ºC. 
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Electro Transformation 
MGl655folA::kan3 cells prepared above were thawed on ice and 80 µl 
cells were transferred to each of 10 sterile microcentrifuge tubes. To 
each tube 10 ng of DNA were added according to the schedule below 
(Table 7) 
Table 7. Reaction set up for electro transformation of MG1655folA::kan3 cells with 
plasmid DNA of the recombinant wild type and mutant M. avium DHFR. 
Cells Plasmid DNA 
MG1655folA::kan3 no DNA added 
MG1655folA::kan3  p807 recombinant wild type DHFR 
MG1655folA::kan3 D31A mutation 
MG1655folA::kan3 D31E mutation 
MG1655folA::kan3 D31Q mutation 
MG1655folA::kan3 D31N mutation 
MG1655folA::kan3 D31L mutation 
MG1655folA::kan3 V76A mutation 
MG1655folA::kan3 pET15b vector only 
MG1655folA::kan3 Vector pGEM11z(f) + only 
 
It was necessary for the DNA to be very clean, (i.e. no salt) in order 
for the gene pulser apparatus not to arc. Tubes were allowed to sit on 
ice for 1 minute. The gene pulser apparatus were set 25 µF and 2.5kV. 
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The pulse controller was set at 200Ω. 
The cell /DNA mixture was transferred to chilled 0.2 cm 
electroporation cuvettes (BioRad) and tapped gently to remove any 
bubbles.  Cuvettes were placed in the chamber slide and pushed into 
the chamber, until the curette was seated between the contacts in the 
base of chamber, and pulsed once at the above settings.  The time 
constant were recorded. The cuvettes were then removed and 1 ml 
SOC medium (Invitrogen) was added immediately to the cuvettes. The 
cells were then transferred to a sterile micro centrifuge tube or a small 
sterile snap cap tube and incubated for 1 hour at 37ºC and 225 rpm 
(rotary aeration). For each reaction, 100 µl was plated on LB-Agar, 
containing 30 µg/ml kanamycin, 50 µg/ml thymidine and 100 µg/ml 
carbenicillin. The plates were incubated overnight at 37ºC (Isotemp 
incubator, Fischer Scientific). An isolated colony was selected and 
grown overnight in 12.5ml LB-medium containing 30 µg/ml 
kanamycin, 50 µg/ml thymidine and 100 µg/ml carbenicillin. 
Growth assay with thymidine 
The overnight culture was used (~ 50 µl) to inoculate 30 ml LB-
medium (30 µg /ml kanamycin, 50 µg/ml thymidine and 100 µg/ml 
carbenicillin) to achieve an OD600 of 0.008 – 0.011. This set up 
culture was further diluted as follows: 25 ml was combined with 
additional 25 ml fresh LB-medium containing 30 µg/ml kanamycin, 50 
µg/ml thymidine and 100 µg/ml carbenicillin (1:1 dilution) in 125 ml 
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sterile flasks. An OD600 reading was taken for the time point t=0. 
This sample was serially diluted (10-1 – 10-7) with sterile H2O and 10 
µl of each dilution plated on LB-Agar with the same antibiotic 
conditions as above. The cultures were grown at 37ºC and 225 rpm. 
Samples were taken after 2, 4, 6 and 8 hours. For each interval an 
OD600 reading was taken and samples were serially diluted as plated 
on LB-agar (see above). The agar plates were incubated at 37ºC 
(Isotemp incubator, Fischer Scientific) overnight (about 15 hours) and 
plates were used to determine CFUs. A growth curve was constructed 
by plotting CFU/ml against time. 
Growth assay without thymidine 
Freshly transformed cells that were grown overnight on LB-agar with 
thymidine, were used to streak LB-agar that contained 30 µg/ml 
kanamycin and 100 µg/ml carbenicillin, but no thymidine. It was 
necessary to add IPTG to a final concentration of 0.1 mM to the 
growth medium that did not contain thymidine. The same procedure 
was followed as described above in the growth assay with thymidine. 
A growth curve was also constructed by plotting CFU/ml against time. 
Circular dichroism 
Circular dichroism spectra were obtained at 25ºC with a Jasco-715 
spectropolarimeter using a 0.1-cm path length cell over the 195-260 nm range. 
The spectra were acquired every 1 nm with a 2-s averaging time per point and a 1-
nm band pass. Quadruplicate measurements of each sample were averaged, 
corrected for background and smoothed. The proteins were dissolved in 20 mM 
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sodium phosphate, 100mM NaCl, pH 7.4 and the protein concentration was 
determined by UV absorption spectroscopy using an extinction coefficient, at 
280nm, of 39,500 M-1cm-1. The mean residue ellipticity (MRE in deg.cm2.dmol-1) 
was calculated from the number of residues of the recombinant DHFR. The 
secondary structure of the proteins, including regular and distorted α-helix, 
regular and distorted β-sheet, turns, and unordered structures, was estimated with 
according to Sreerama et al. ((56), with the program SELCON3 using a 29-
protein data set of basic spectra.  
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CHAPTER III 
RESULTS 
Mutagenesis 
Sequencing data showed that the GeneEditor (Promega) mutagenesis protocol used to 
construct the M. avium DHFR mutants used in this study was not only successful, but 
highly efficient. Efficiencies of 80% and higher were achieved. This shows the 
considerable improvement of mutagenesis protocols as routine research tools when 
compared to mutagenesis studies done in the 1980s. Then efficiencies were between 5 
and 30% (54, 64, 68). For their mutagenesis experiments of aspartic acid 27 in E. coli, 
Villafranca et al. (64) achieved a mutagenesis efficiency of only 0.3%. 
The far-UV CD spectra of recombinant wild type M. avium DHFR and the mutations 
D31A, D31E, D31Q, D31N, D31L and L32D are shown in Figure 7. Consistent with the 
α/β sheet motif, the spectra of the proteins show a minimum at 215nm and becomes 
positive below 200 nm. The estimates of the four structural components (α-helix, β-sheet, 
β-turns and unordered) are listed in Table 16. Three of the mutants (D31A, D31E and 
L32D) have CD spectra (Panel A-Fig 7), and deduced secondary structure (Table 16), 
which are nearly identical to the spectrum of the wild type M. avium DHFR.  However, 
the spectra of the D31L, D31N and D31Q mutations show differences with the spectra of 
the wild type protein. Replacement of D31 by leucine, asparagine and glutamine appears 
to have resulted in a reduction of the β-sheet content of the mutant enzymes.  
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Figure 7:Far-UV CD spectra of recombinant wild type and mutant M. avium DHFR. 
Spectra were acquired in 20mM sodium phosphate, 100mM NaCl, pH 7.4 and 
25 °C. For clarity the spectra are represented in two panels. With exception of 
the spectrum for the L32D mutant, which was obtained from a single protein 
sample, the spectra shown represent the average obtained from at least two 
independent protein preparations. Protein names and corresponding symbols are 
indicated in the figure.   
 
Protein expression and purification 
Sufficient amounts of soluble recombinant mutant proteins (at least 50% or higher) were 
obtained from expression in E. coli BL21(DE3)pLysS cells.  
His-Bind resin (Novagen) was used to recover recombinant wild type and mutant M. 
avium DHFR from the soluble fraction of a cell extract under non-denaturing conditions. 
In this semi-automated process, His-Bind resin columns were loaded and washed 
manually and by gravity flow until the flow through showed no significant reading at 280 
nm. The automated elution of the His-Bind resin bound protein with a 5 – 500 mM 
imidazol linear gradient is shown in Figure 8 for the recombinant wild type DHFR.  
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Figure 8:Semi-automated purification scheme of recombinant wild type DHFR on His-
Bind resin (Novagen) with a linear gradient of 5-500 mM imidazol  
A. UV absorbance profile of Biologic LP UV monitor (BioRAD) of elution 
B. Coomassie-blue stained SDS-PAGE gel (12.5% Tis-HCl) of His-Bind resin eluted 
fractions  
Lane 1: Novagen Perfect Protein Markers (kDa sizes indicated on the left) 
Lane 2: Precolumn protein extract 
Lane 3: Flow through 
Lane 4: Wash 5 mM imisazol 
Lane 5: Wash 40 mM imidazolLane 6-17: Eluted fractions 9- 20 
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The flow through fraction (Figure 8B, lane 3) shows that most DHFR bound to the His-
Bind resin. There is almost no DHFR band visible in the flow through fraction. However, 
the low imidazol fractions (5 and 40 mM) in lanes 4 and 5 indicate that some of the 
binding to the His-Bind resin was non-specific. The bound protein eluted between 150 
and 300 mM imidazol, with the peak of the elution profile being around 300 mM 
imidazol (Figure 8A). The elution profile for the recombinant wild type and mutant 
DHFR were very consistent and similar. Table 8 shows the amount of active enzyme 
recovered as well as the overall yield in purified DHFR. The percentage yield of 
sufficiently clean active enzyme in this case was 33.7%. This corresponds to an increase 
in fold purification of between 10 and 14 times. 
 
Fraction  Fraction Volume  
Protein 
conc.mg/ml  ΔA340  
Total 
Activity  
Total 
Protein 
Specific 
Activity Yield 
Fold 
Purification 
 ml mg/ml µmole/min/ml µmole/min mg µmole/min/mg %  
PreColumn 
Extract 10.0 44.0 47.6 767 7042.78 1.08 100 -- 
E10 2.0 ml 1.39 12.9 25.8 2.78 10.4 3.39 9.63 
E11 2.0 ml 2.33 29.3 58.6 4.66 12.6 7.69 11.7 
E12 2.0 ml 2.4 31.7 63.4 4.80 13.2 8.33 12.2 
E13 2.0 ml 2.05 27.6 55.2 4.10 13.5 7.25 12.5 
E14 2.0 ml 1.46 15.5 31.0 2.92 10.6 4.07 9.82 
E15 2.0 ml 0.618 6.67 13.3 1.24 10.7 1.75 9.91 
E16 2.0 ml 0.301 4.63 9.26 0.602 15.4 1.22 14.3 
Totals             33.7   
Table 8 Semi-automated purification of recombinant wild type DHFR on His-Bind resin (Novagen) with a linear gradient 
of 5-500 mM imidazol 
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Aspartic acid 31 mutations 
Specific activity 
His-Bind resin eluted fractions were assayed for enzyme activity in an in vitro enzyme 
assay and the results show a significant reduction in enzyme specific activity for all the 
D31 mutants assayed. (D31A, D31E, D31Q, D31N and D31L). Tables 9 and 10 below 
show that although these recombinant mutant M. avium DHFRs still display 
functionality, the activity is significantly reduced. D31A and D31L show a reduction in 
enzyme activity of over 90% while D31E, D31Q and D31N show a reduction of 81.1%, 
85.3%  and 84.6%, respectively as compared to the recombinant wild-type M. avium 
DHFR.  However, the negative control mutation V76A did not show a reduction in 
activity compared to the recombinant wild type. 
Using the SAS statistical software (SAS system for Windows V8, SAS Inst. Inc, NC, 
USA), the Dunnett’s Test shows (at significance level alpha = 0.05) that with the 
exception of the control mutation V76A, the enzyme specific activity of all D31mutations 
are significantly different from that of the recombinant wild type p807 (Table 9).  
The control mutation V76A outside the enzyme’s active site still has a specific activity 
that amounts to 98.7% of that of the recombinant wild type and is therefore statistically 
not different from the wild type. 
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Table 9.Comparison of enzyme specific activity (µmole min-1 mg-1) of D31 mutated 
(D31A, D31E, D31Q, D31N, D31L) and control mutant (V76A) DHFR to that 
of the recombinant wild type (p807) at pH 7.0 and 30°C using the ANOVA and 
Dunnett procedures in the SAS statistical software (SAS system for Windows 
V8, SAS Inst. Inc, NC, USA) Dunnett significance level α = 0.05 
DHFR Specific Activity µmole min-1 mg-1
% relative 
specific activity 
% decrease in specific 
activity over wild type 
Dunnett 
Alpha=0.05 
 
p807 
 
15.4 
 
100 
 
== 
 
== 
D31A 1.05 6.82 93.2 P < 0.0001 
D31E 2.91 18.9 81.1 P < 0.0001 
D31Q 2.26 14.7 85.3 P < 0.0001 
D31N 2.37 15.4 84.6 P < 0.0001 
D31L 0.060 0.39 99.6 P < 0.0001 
V76A 15.2 98.7 1.30 P = 0.914 
 
In a multiple comparison, also using the SAS statistical software, the TUKEY post-test 
shows, that although all the D31 mutants are significantly different from the recombinant 
wild type in their specific enzyme activity, they are not all significantly different among 
themselves (Table 10A). 
Table 10B shows that there are 3 groups, where DHFRs with the same group letter are 
not significantly different from each other, but significantly different to DHFRs in the 
other groups. 
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Table 10.Multiple comparison of enzyme specific activity  (µmole min-1 mg-1)of 
recombinant wild type (p807) and D31mutated (D31A, D31E, D31Q, D31N, 
D31L) as well as control (V76A) DHFR at pH 7.0 and 30°C using the ANOVA 
and TUKEY procedures in the SAS statistical software (SAS system for 
Windows V8, SAS Inst. Inc, NC, USA) . TUKEY significance level α = 0.05.  
A. Individual comparison with P-value.  
B.  Mutants without significant differences appear in the same row (same group letter), 
while mutants with significant differences appear in different rows (different group 
letters)  
 
A 
mutations 
compared P value 
mutations 
compared P value 
D31A D31E < 0.0001 D31L D31N < 0.0001 
D31A D31L < 0.0001 D31L D31Q < 0.0001 
D31A D31N < 0.0001 D31L p807 < 0.0001 
D31A D31Q < 0.0001 D31L V76A < 0.0001 
D31A P807 < 0.0001 D31N D31Q 0.924 
D31A V76A < 0.0001 D31N p807 < 0.0001 
D31E D31L < 0.0001 D31N V76A < 0.0001 
D31E D31N 0.252 D31Q p807 < 0.0001 
D31E D31Q 0.169 D31Q V76A < 0.0001 
D31E p807 < 0.0001 p807 V76A 1 
D31E V76A < 0.0001     
 
 
B 
 GROUP DHFR 
A P807 V76A      
B    D31E D31N D31Q   
C       D31A D31L 
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Kinetic characteristics of D31 mutant DHFR 
The kinetic parameters Km and Vmax for FAH2 and NADPH of the recombinant wild type 
M. avium DHFR (p807) and its D31mutants were determined using the non-linear 
Michaelis-Menten curve fitting program Enzfitter (Biosoft, UK) (Figure 9) and are listed 
in Table 11. The D31A and D31L mutants show the greatest changes in kinetic 
characteristics compared to the recombinant wild type (p807). The Km(FAH2) is 37 µM 
for D31A and 198µM for D31L compared to the 0.70 µM for p807. This corresponds to a 
51-fold increase for D31A and a 283-fold increase for D31L. 
The Km(FAH2) for D31E, D31Q and D31N is 1.92, 2.32 and 2.08 µM, respectively; a 
moderate increase of between 2 and 2.5-fold over p807. On the other hand D31Q and  
D31N show a slight decrease in their Km(NADPH): 0.65 and 0.77 µM, respectively. With 
a Km of 2.01 µM, D31E shows a slight increase in Km(NADPH) over the recombinant 
wild type. In contrast to its Km(FAH2) that showed a 283-fold increase, the Km(NADPH) 
value of 1.44 µM of the D31L mutant is not very much different from that of the 
recombinant wild type. The D31A, D31Q and D31L mutants had the lowest 
kcat/Km(FAH2) values: 2.30 x 104, 6.50 x105 and 1.26 x 102, s-1M-1 respectively,  while 
D31E and D31N were very similar with 1.87 x 106 and 2.4 x 106 s-1M-1, respectively 
(Table 11).  
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 Figure 9:Determination of Michaelis-Menten parameters Km(FAH2) and Vmax(FAH2) of 
recombinant wild type M. avium DHFR (p807) at pH 7.0 and 30°C using the 
non-linear curve fit program Enzfitter (Biosoft, UK). Reaction was initiated by 
addition of enzyme after the substrates dihydrofolate and NADPH were 
incubated at 30°C for 1 minute. Absorbance was measured at 340 nm for 
minute in a Spectronic Genesis 5 spectrophotometer in kinetic mode with 10 
second reading intervals. 
 
Km(NADPH) for the D31A mutant was with 0.68 µM similar to that of the mutants D31Q 
and D31N.  The data indicate that the control mutation V76A did not affect the Km for 
both FAH2 and NADPH. This mutant had a Km(FAH2) of 0.78 µM compared to 0.7 µM 
of the recombinant wild type. The Km(NADPH) of the V76A control mutant was 1.56 µM 
compared to 1.55 µM of the recombinant wild type.  
For both substrates there was more variation in Vmax among the D31 mutants, than there 
was in Km.  The Vmax(NADPH) of the V76A control mutant was the only one that was not 
much different from the recombinant wild type.  
The data indicate that the control mutation V76A did not affect the Km for both FAH2 and 
NADPH (Table 11).  
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Table 11:Kinetic parameters at pH 7.0 and 30°C of recombinant wild type and 
D31mutants of M. avium DHFR for FAH2 and NADPH determined with the 
non-linear Michaelis-Menten curve fitting program Enzfitter (BioSoft, UK). 
DHFR K m V max k cat k cat /K m K m V max
(µM) µmole min-1 mg-1 sec-1 s-1 M-1 (µM) µmole min-1 mg-1
p807 0.7 61.1 20.5 2.90x107 1.55 80
D31A 37 2.57 0.86 2.30x+104 0.68 1.76
D31E 1.92 10.7 3.58 1.87x106 2.01 6.16
D31Q 2.32 4.51 1.5 6.5010x5 0.65 6.53
D31N 2.08 15.1 5.03 2.40x106 0.77 25.5
D31L 198 0.076 0.025 1.26x102 1.44 0.06
V76A 0.78 56.4 18.7 2.40x107 1.56 71.3
FAH2 NADPH
 
 
Growth complementation  
The DHFR-deficient E. coli strain MG1655folA::kan3 (folA-) was transformed with 
plasmid DNA of the recombinant wild type M. avium DHFR (folA-p807), as well as that 
of the aspartic acid 31 mutants (folA-D31A, folA-D31E, folA-D31Q, folA-D31N, folA-
D31L)  and the mutation control V76A (folA-V76A). In addition, the DHFR-deficient 
strain was also transformed with plasmid DNA of the pET15b vector that did not contain 
the M. avium DHFR gene insert (folA-pET15b). 
Figure 10A below shows that all cells show similar and normal growth, comparable to 
that of the parent strain MG1655, when grown in the presence of thymidine.  
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When, however, the DHFR-deficient strain transformed with plasmid DNA that carried 
the M. avium DHFR gene (recombinant wild type p807) as well as the various D31 
mutations, respectively, was cultured in the absence of thymidine, only the wild type 
(p807) and the control mutation V76A showed growth of the DHFR-deficient strain to 
levels comparable to that of the E. coli MG1655 parent strain (Figure 7B). Neither the 
DHFR-deficient E. coli MG1655folA::kan3 (folA-) strain nor any of the D31 mutants 
showed any significant growth. The DHFR-deficient strain that was transformed with the 
pET15b Vector that did not contain the M. avium DHFR gene also did not show any 
growth (Figure 10B).  
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Figure 10:Growth curve at 37°C and 225 rpm of DHFR-deficient E. coli strain 
MG1655folA::kan3 transformed with recombinant wild type M. avium DHFR 
(p807), D31 mutants and the controls (V76A and pET15b vector only). Growth 
in the presence of thymidine (A) and growth in the absence of thymidine (B) 
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 Leucine 32 mutations 
Specific activity 
In contrast to the aspartic acid 31 (D31) mutations only one of the 3 L32 
mutations of M. avium DHFR caused a significant change in the mutant enzyme’s 
specific activity as compared to the recombinant wild type enzyme (Table 12). 
Both the L32F and the L32A mutations did not have an impact on the enzyme’s 
interaction with the substrate dihydrofolate. Compared to the recombinant wild 
type, the L32F mutation had a slightly higher relative specific activity (103%), 
showing that statistically (Dunnett’s test P=0.759 at α = 0.05) this mutation was 
not different from the recombinant wild type (Table 12). The L32A mutation of 
the M. avium DHFR still had 96% of the specific activity of the recombinant wild 
type enzyme, therefore statistically (Dunnett’s test P=0.742 at α = 0.05) not 
different from the recombinant wild type. The L32D mutation was the only one of 
the 3 mutations in this series that had a negative impact on the mutant enzyme’s 
activity. This mutant had a 67% reduction in its specific activity as compared to 
the recombinant wild type and was therefore found to be statistically different 
from the recombinant wild type (Dunnett’s test P<0.0001 at α = 0.05). 
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Table 12. Comparison of enzyme specific activity (µmole min-1mg-1) of L32 mutated 
(L32F, L32A, L32D ) DHFR to that of the recombinant wild type (p807) at pH 
7.0 and 30°C using the ANOVA and Dunnett procedures in the SAS statistical 
software (SAS)system for Windows V8, SAS Inst. Inc, NC, USA) Dunnett 
significance level α = 0.05 
 
The Dunnett’s test only compared each mutant to the wild type for differences, 
not the mutants among themselves. In a multiple comparison test using SAS 
statistical software (SAS system for Windows V8, SAS Inst. Inc, NC, USA), the 
TUKEY-post-test showed that the L32F and L32A mutants were not statistically 
different from each other (P=0.370 at α = 0.05), but that they were each 
statistically different from the L32D mutations (P<0.0001 at α = 0.05 for both 
cases). These results are summarized in Table 13A and B.  
p807 15.4 100 - -
L32F 16 103 - P = 0.759
L32A 14.7 96 4 P = 0.742
L32D 5.09 33 67 P  < 0.0001
DHFR % relative specific activity
% decrease in 
specific activity 
over wild type
Dunnett 
Alpha = 0.05
Specific Activity 
µmole min-1mg-1
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Table 13.Multiple comparison of enzyme specific activity (µmole min-1mg-1) of 
recombinant wild type (p807) and mutated (L32F, L32A, L32D) M. avium 
DHFR at pH 7.0 and 30°C using the ANOVA and TUKEY procedure in the 
SAS statistical software (SAS system for Windows V8, SAS Inst. Inc, NC, 
USA). (TUKEY significance level alpha=0.05).  
A. Individual comparison with P-value:  
B. Mutants without significant differences appear in the same row (same group 
letter),while mutants with significant differences appear in different rows (different 
group letters)  
A 
mutations 
compared P value 
p807 L32F 0.85 
p807 L32A 0.838 
p807 L32D <0.0001
L32F L32A 0.37 
L32F L32D <0.0001
L32A L32D <0.0001
 
 
  B 
GROUP DHFR 
A p807 L32F L32A  
B     L32D 
 
 
Kinetic characteristics of L32 mutant DHFR 
The kinetic parameters Km and Vmax for dihydrofolate (FAH2) and NADPH were 
also determined at pH 7.0 and 30°C using the non-linear Michaelis-Menten curve 
fitting program Enzfitter (Biosoft, UK) and are listed in Table 14 for the 
recombinant wild type and the L32 mutants of M. avium DHFR. The L32F and 
L32A mutants were not very different from the recombinant wild type in 
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Km(FAH2) values. The Km(FAH2) of the recombinant wild type was 0.7µM, while 
that of the L32F mutant was 0.68 µM. The L32A mutant had a slightly higher 
Km(FAH2) of 0.96 µM. With a Km(FAH2) of 5.12 µM, the L32D had a 7-fold 
increase in Km(FAH2) over the recombinant wild type.  
The mutants L32F and L32A were also not much different from the recombinant 
wild type in their Vmax(FAH2) values. The recombinant wild type had a 
Vmax(FAH2) of 61.1 µmole min-1 mg-1, while the L32F and L32A mutants had a 
Vmax(FAH2) of 63.3 and 55.2 µmole min-1 mg-1, respectively. The mutant L32D 
had a Vmax(FAH2) of 21.5 µmole min-1 mg-1; a value almost 3-fold lower than the 
recombinant wild type (Table 14).  
The L32F mutant’s kcat/Km(FAH2) was just slightly higher than the recombinant 
wild type. The kcat/Km(FAH2) of the L32F mutant was 3.09x107 s-1M-1, whereas 
that of the recombinant wild type was 2.90x107 s-1M-1. The L32A mutant of M. 
avium DHFR had a lower kcat/Km(FAH2) compared to the recombinant wild type. 
With a kcat/Km(FAH2) value of 2.0x107 this mutant’s kcat/Km(FAH2) value was 
almost 1.5-fold lower than that of the recombinant wild type. On the other hand 
the L32D mutant had a kcat/Km(FAH2) value of 1.41x106 s-1M-1 which was almost 
21-fold lower than that of the recombinant wild type (Table 14). 
The recombinant wild type M. avium DHFR and the mutants L32F and L32A 
were also similar with respect to NADPH binding. The recombinant wild type had 
a Km(NADPH) of 1.55 µM, whereas that of the L32F and L32A mutants were 
1.32  and 1.39µM, respectively. The Km(NADPH) of the L32D mutant was 0.84 
µM and therefore almost 2-fold lower than that of the recombinant wild type. The 
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recombinant wild type and the L32F and L32A mutants had a Vmax(NADPH) of 
80, 69.6 and 53.5 µmole min-1 mg-1, respectively (Table 14), whereas 
Vmax(NADPH) of the L32D mutant was 30.1 µmole min-1 mg-1. 
 
 
Table 14.Kinetic parameters at pH 7.0 and 30°C of recombinant wild type and L32 
mutants of M. avium DHFR for FAH2 and NADPH determined with the non-
linear Michaelis-Menten curve fitting program Enzfitter (BioSoft, UK). 
  FAH2 NADPH 
DHFR Km Vmax kcat kcat/Km Km Vmax
  (µM) (µmole min-1mg-1) sec-1 s-1 M-1 (µM) (µmole min-1mg-1)
p807 0.7 61.1 20.5 2.90 x 107 1.55 80 
L32F 0.68 63.3 21 3.09 x 107 1.32 69.6 
L32D 5.12 21.5 7.2 1.41 x 106 0.84 30.1 
L32A 0.96 55.2 16.2 1.69 x 107 1.39 53.5 
 
 
 
Growth complementation 
As shown in Figure 11, the L32F and L32A mutants of the M. avium DHFR was 
able to complement the DHFR-deficient strain E. coli MG1655folA::kan3 and 
restored growth of the deficient strain to levels comparable to its parent strain  
E. coli MG1655. The DHFR-deficient strain E. coli MG1655folA::kan3 grew 
when supplemented with thymidine (Figure 10A, folA-), but did not grow in the 
absence of thymidine (Figure 11B, folA-). When transformed with plasmid DNA 
of M. avium DHFR mutants L32F and L32A, the DHFR-deficient E. coli 
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MG1655folA::kan3 strain was able to grow in the absence of thymidine, 
indicating that these DHFR mutants of M. avium was able to restore DHFR 
activity to E. coli and thereby restore growth (Figure 11B, folA-L32F and folA-
L32A ). The L32D mutant did not restore growth of the DHFR-deficient strain to 
levels comparable to the E. coli parent strain MG1655, but was able to cause 
partial growth in the deficient strain (Figure 11B, folA-L32D). 
Inhibitor IC50 assay 
After the appropriate amount of enzyme to be used in the IC50 assay was 
determined in the standard assay, the IC50 assay was performed similarly to the 
standard enzyme assay, with the exception that the 1 ml enzyme reaction 
contained both the enzyme and the inhibitor, pre-incubated in a water bath at 
30°C for 3 minutes. The reaction was initiated by addition of dihydrofolate and 
measured in kinetic mode for 3 minutes at 340 nm. 
The IC50 values were then computer using the 4- parameter curve program in the 
KC-Junior software (Bio-TEK, VT, USA). The 4-parameter curves for the 
recombinant wild  
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Figure 11:Growth curve at 37°C and 225 rpm of DHFR-deficient E. coli strain 
MG1655folA::kan3 transformed with recombinant wild type M. avium DHFR 
(p807), L32F mutant and control pET15b vector only. Growth in the presence 
of thymidine (A) and growth in the absence of thymidine (B).  
type, as well as the L32A and L32D mutants are displayed in Figure 12. The IC50 
values of the recombinant wild type and the L32F mutant of M. avium DHFR for 
trimethoprim were very similar with 3869 and 3647 nM respectively. The IC50 
value of the L32A mutant for trimethoprim, however, was with 45067 nM, about 
12-fold higher than that of the recombinant wild type (Table 15). On the other 
hand the L32D mutant’s IC50 value for trimethoprim was 570 nM, which was 
about 7-fold lower than that of the recombinant wild type.  
Compared to trimethoprim, the SRI deazapteridines showed a greater selectivity 
for the wild type M. avium DHFR but that selectivity was reduced by the various 
L32 mutations. The IC50 value of the recombinant wild type for SRI compounds 
8858 and 20730 were 1.03 and 1.96 nM, respectively (Table 15). The IC50 values 
of compounds 8858 and 20730 for the L32F mutant were 14.8 and 41.7 nM, 
respectively. Compared to trimethoprim this amounts to a reduction of 246 and 
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88-fold, respectively for the SRI compounds.  The reduction of the IC50 of the 
L32A mutant of M. avium DHFR was only moderate for both SRI compounds. 
The L32A mutant had an IC50 of 507  nM for compound 8858 and 861 nM for 
compound 20730 (Table 15). This represents a reduction of between 52 and 88-
fold between these 2 compounds when compared to trimethoprim. The reduction 
in the IC50 values of the L32D mutant for the SRI compounds were very small, 
between 4 and 8-fold, compared to trimethoprim. The L32D mutant had an IC50 
of 69 nM for compound 8858 and 134 nM for compound 20730 (Table 15). 
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Figure 12: Four parameter curves for determination of IC50 relative concentrations of SRI 
compound 8858 for recombinant wild type, L32D and L32A mutants of M. 
avium DHFR. 
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Table 15. IC50 of trimethoprim (TMP) and SRI compounds 8858 and 20730 for 
recombinant wild type and leucine 32 mutant M. avium DHFR as determined by 
the 4 parameter curve procedure (the Bio-TEK enzyme software). 
 
 
 
 
 
 
DHFR\DRUG TMP [nM] 
SRI 8858 
[nM] 
SRI 20730 
[nM] 
WT 3869 1.03 1.96 
L32F 3647 14.8 41.7 
L32A 45067 507 861 
L32D 570 69 134 
 
 
Table 16. Estimated relative amounts of secondary structural components of recombinant 
wild type M. avium DHFR and and D31 and L32 mutants. The fractions of the 
different structural components were calculated from the data shown in Figure 7 
using the program Selcon3. 
 
 
 
 α-helix β-sheet β-Turn Unordered 
WT 0.20 0.38 0.17 0.25 
D31A 0.20 0.38 0.17 0.25 
D31E 0.20 0.35 0.15 0.22 
D31L 0.19 0.28 0.22 0.30 
D31N 0.15 0.30 0.23 0.31 
D31Q 0.29 0.20 0.24 0.30 
L32D 0.12 0.30 0.19 0.27 
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CHAPTER IV 
DISCUSSION 
The mutagenesis procedure was highly efficient, delivering 80% and higher successful 
mutants as confirmed by complete gene sequencing. The control mutation V76A, which 
was outside the enzyme binding cavity, did not alter the enzyme’s interaction with the 
normal substrate as compared to the recombinant wild type enzyme, thereby suggesting 
that the mutation process did not have a negative impact on the enzyme’s proper folding. 
The far-UV CD spectra of recombinant wild type M. avium DHFR and its D31 and L32 
mutants (Figure 7, Table 16) show that the inferred secondary structure of wild type M. 
avium DHFR is consistent with the crystal structures of the homologous DHFR from M. 
tuberculosis (35), and E. coli (10), whose structures comprise eight β strands and four α-
helices.  The structural information obtained by CD spectroscopy is also consistent with 
the homology model of M. avium (33) . 
 
The use of the pET15b vector in the site-directed mutagenesis procedure, instead of the 
pGEM11zf(+) subcloning vector of the GeneEditor kit, circumvented multiple subcloning 
and excision steps. The same pET15b vector was used for cloning, mutagenesis and 
expression of the mutant and wild type target protein. This was possible, because 
essentially any plasmid vector that carries the ampicillin resistance gene could be used 
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with this mutagenesis kit. The pET15b vector further added an N-terminal his-tag to the 
expressed target protein that eventually aid in the purification of the target protein.  
The expression of the recombinant target protein in E. coli BL21(DE3) pLysS took place 
at 28°C in order to minimize the expression of endogenous E. coli DHFR in comparison 
with the IPTG induced over-expression of the target protein.  At least 50% of expressed 
target protein was recovered in the soluble protein fraction. The recovery of DHFR from 
the soluble extract varied from 60 – 80%, with at least half of that amount as sufficiently 
clean target protein (Figure 8 and Table 8). 
Functionality of M. avium conserved aspartic acid 31 (D31) mutants 
Site-directed mutagenesis has previously been used to investigate the role of this highly 
conserved carboxylic acid residue in catalysis and binding in E. coli, L. casei and a few 
other species (2, 7, 19, 29, 30, 62, 64). This is the first study that has assessed the 
important functional role of the conserved D31 residue in M. avium, or any other 
equivalent residue in any other mycobacterial DHFR.  
All mutations of the aspartic acid 31 (D31) affected the enzyme negatively and showed a 
significant reduction in the enzyme’s interaction with dihydrofolate, the natural substrate. 
The substitution  D31A  removed the side chain and the charge at that position altogether 
which resulted in a reduction of the enzyme’s specific activity by almost 95%. This 
indicates the important functional role of this residue in M. avium DHFR in interacting 
with the normal substrate, dihydrofolate. This is also consistent with this residue’s role in 
other DHFRs described thus far and a reflection of the strictly conserved status of this 
residue for all known DHFR’s.  (1, 3, 11, 22, 30, 34, 40, 44, 46, 60, 64). The D31E 
mutation that retained the important carboxylic acid group of the wild type, but is one 
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methylene group larger than the recombinant wild type, had its specific activity reduced 
by around 80%, suggesting that the larger side chain did have a negative effect on 
interactions within the binding cavity. The D31Q mutation which is also one methylene 
group larger than the recombinant wild type enzyme and has the same size as the D31E 
mutant, did not have the charge of the carboxylic acid group as the recombinant wild type 
or the D31E mutant. Nonetheless, this mutation also showed a reduction in specific 
activity of over 80% of the activity of the wild type; in magnitude about the same as the 
D31E mutation (Table 9). 
 
The D31N and D31L mutations both have the same side chain size as the recombinant 
wild type’s aspartic acid, however, although the D31N is not charged, it is nonetheless 
polar, while the D31L side chain is not charged and non-polar. With respect to side chain 
size and volume the D31 is almost super imposable with the mutant side chains D31N 
and D31L. The D31N mutant showed a reduction in specific activity of around 85% over 
the recombinant wild type, and therefore, behaved similarly as the D31E and D31Q 
mutations. The D31L mutation on the other hand had less than one percent of the specific 
activity of the recombinant wild type, and therefore, could be considered similar to the 
D31A mutation in terms of the amount of enzyme functionality displayed (Table 9). The 
V76A modification was a mutation outside of the enzyme’s binding cavity and did not 
show a change in the enzyme’s specific activity as compared to the recombinant wild 
type. This validated the mutation procedure, and therefore, it can be argued that the 
change in the observed reduction of the mutant enzymes’ specific activity was a result of 
the change of the conserved aspartic acid.  
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Statistical analysis (ANOVA with Dunnett and Tukey) showed that all the D31 mutant 
enzymes in this study were significantly different from the recombinant wild type in 
terms of their specific activity (Table 9). However, some of the mutations were not 
significantly different from each other (Table 10). Although the D31E, D31Q and D31N 
mutations were remarkably different in terms of side chain size and charge, they were not 
statistically different from each other in terms of enzyme functionality. This group was 
distinctly and statistically different from the other mutations and the recombinant wild 
type (Table 10B). The D31A and D31L mutations also represent marked diversity, yet 
they formed another group with no significant difference in functionality between them, 
but statistically different from the recombinant wild type and the other mutations (Table 
10B). The control mutation V76A was the only mutation that was statistically similar to 
the recombinant wild type in functionality and therefore together with the recombinant 
wild type formed a third group of enzymes that was distinctly different from the mutant 
enzymes (Table 10B). 
Birdsall et al. (7) found that a D26E mutation in L. casei (the equivalent position of D31 
in M. avium) still had 90% of the specific activity of the wild type enzyme. They also 
found that there were no major changes in the overall structure of the mutant enzyme. 
Local perturbations observed might have been necessary to accommodate the larger side 
chain. David et al. (18) on the other hand found  that although a D27E mutant E. coli 
DHFR was still able to catalyze the reduction of dihydrofolate to tetrahydrofolate, the 
mutant enzyme was 17-fold less efficient than the wild type enzyme.  They also did not 
observe any structural changes in an X-ray crystal structure of the E. coli D27E DHFR. 
The kinetic parameters of the recombinant wild type and D31 mutants of the M. avium 
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DHFR for this study are listed in Table 11. The M. avium DHFR D31E mutant had a 
Km(FAH2) of 1.92 µM; about a 3-fold increase over the recombinant wild type, which had 
a Km(FAH2) of 0.7 µM. However, the D31E mutant had a kcat(FAH2) of 3.58 sec-1, 
compared to 20.5 sec-1 of the recombinant wild type. Therefore, this mutant showed only 
a 6-fold decrease in kcat (catalytic efficiency), but a 16-fold decrease in kcat/km (substrate 
specificity) over the wild type (Table 11). The latter value is similar and comparable to 
those obtained by David et al. (18) for the same mutation in E. coli. David et al. (18) also 
pointed out that L. casei DHFR in certain aspects, e.g. its ability to reduce folate, 
resembles more DHFRs of vertebrates than that of bacteria. These differences could in 
part explain the differences observed with regard to the substitution of the conserved 
aspartic acid with glutamic acid in M. avium, E. coli and L. casei. Lactobacillus casei 
also has a conserved aspartic acid in this position, but vertebrates have a glutamic acid. 
The M. avium DHFR mutants D31E, D31Q and D31N in this study were very similar 
with Km(FAH2) of 1.92, 2.32 and 2.08 µM, respectively (Table 11). This represents about 
a 3-fold increase in Km(FAH2) over the recombinant wild type for each of these 3 
mutations and reflects the strong decrease in functionality (specific activity) observed 
earlier (Table 9).  However, these mutants showed more variations in Vmax(FAH2) and 
kcat(FAH2) (Table 11). With a kcat(FAH2) of 5.03 sec-1, D31N was more similar to D31E 
kcat(FAH2) 3.58 sec-1, than to D31Q, that had a kcat(FAH2) of 1.50 sec-1. The D31N and 
D31E mutants also had similar reductions in kcat(FAH2): 4 and 6-fold respectively, was 
well as in kcat/Km(FAH2):  a 12 and 16-fold reduction respectively. On the other hand, the 
D31Q mutant had a 14-fold reduction in kcat(FAH2) and a 45-fold reduction in 
kcat/Km(FAH2). Howell et al. (30) substituted the conserved aspartic acid 27 in E. coli 
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DHFR with asparagine (D27N) and found a severely crippled enzyme. That mutant 
enzyme had less than 1% of the specific activity of the wild type and also severely altered 
kinetics (30). With a Km(FAH2) of 44 µM and kcat(FAH2) of 0.10 sec-1 for the E. coli 
DHFR D27N mutant (30),  their values for this mutant were different from those for the 
same M. avium mutant in this study. The wild type parameters of their study were more 
comparable to this study. Basran  et al.  (6) investigated the role of the active site 
carboxylic acid D26 in L.casei DHFR and found that a D26N mutation in recombinant L. 
casei DHFR (equivalent position of M. avium D31 and E. coli D27) had a much smaller 
effect on that mutant enzyme’s functionality, compared to the equivalent mutation in E. 
coli DHFR. The L. casei D26N DHFR had a decrease in kcat(FAH2) of 9-fold, compared 
to 300-fold in E. coli and a decrease in kcat/Km(FAH2) of 13-fold compared to 11000-fold 
in E. coli (6, 30). The equivalent mutation in M. avium DHFR (D31N) in this study 
resembles more L. casei than E. coli. The M. avium D31N mutant DHFR had a 4-fold 
decrease in kcat(FAH2) and a 12-fold decrease in kcat/Km(FAH2) (Table 11). Nonetheless, 
the overall result of these studies show that the asparagine substitution in this position 
affected the enzyme’s activity in E. coli, M. avium and L. casei. From these mutations it 
is evident that with the same charge but larger side chain (D31E), and with the same size 
side chain but no charge (D31N), functionality of the enzyme is severely affected.  
Although the Km(FAH2) of the D31Q mutation was similar to that of the D31E and D31N 
mutations and there was no significant difference in their specific activities, the data 
suggest a difference in kinetics between the D31Q on the one hand and the D31E and 
D31N on the other. The D31Q mutation’s side chain is larger than the wild type aspartic 
acid residue by one methylene group (similar to the D31E mutation’s side chain), and it is 
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not charged, but polar (similar to the D31N mutation’s side chain).  The combination of 
both adverse factors of the other two mutants (larger size and no charge as compared to 
the recombinant wild type aspartic acid) seem to have had an increased negative effect on 
the D31Q mutant enzyme’s specificity for the substrate. The kcat/Km(FAH2) for D31Q had 
decreased by 45-fold, compared to a reduction of only 16-fold for the D31E mutant and 
12-fold for the D31N mutant (Table 11). Nothing has been found in the literature for this 
mutation in this equivalent position on any DHFR.  
The very low specific activity of the mutant D31L of the M. avium DHFR was also 
reflected in the mutants kinetic behavior. The Km(FAH2) of this mutant was 198 µM, a 
283 fold increase over the recombinant wild type. Its kcat(FAH2) of 0.025 sec-1 was a 
reduction of 820-fold and the kcat/Km(FAH2) was reduced over 230, 000-fold over the 
recombinant wild type (Table 11).  David et al. (18) found a D27L mutant enzyme of E. 
coli DHFR similarly dysfunctional. This mutation is identical in side chain size with the 
recombinant wild type aspartic acid, but has no charge and is nonpolar. It is by far the 
most severe change in this position of all the D31 mutants investigated, suggesting that 
the increased hydrophobicity had more severe negative effects than the loss of the charge 
alone.  The D31A mutation that did not show a statistical difference in specific activity to 
the D31L mutation, seems to be different in its kinetic behavior from the D31L mutant. 
The D31A mutant had a Km(FAH2) of 37 µM (Table 11), which represents a 53-fold 
increase over the recombinant wild type.  The kcat(FAH2) decrease over the recombinant 
wild type for the D31A mutation was only 24-fold, but the kcat/Km(FAH2) decrease was 
1261-fold.  Both the D31A and D31L were very low activity mutants with the largest 
increases in Km(FAH2) over the recombinant wild type (Table 11).  However, although 
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they did not show a statistical difference in their specific activity (Table 9 and 10A and 
B) and their Km(FAH2) difference was only 5-fold, the data show a 200-fold difference 
between them in their kcat/Km(FAH2) values (Table 11). With the D31A mutation, the 
charge of the wild type carboxylic acid was removed and at the same time it had the 
smallest side chain of all mutants. This mutation shows that removing the carboxylic acid 
seriously cripples the enzyme. 
The recombinant wild type and the control mutation V76A were not very different in 
their kinetics for both dihydrofolate and NADPH. The recombinant wild type had a 
Km(FAH2) of 0.7 µM, whereas V76A had a Km(FAH2) of  0.78 µM (Table 11).  The 
Vmax(FAH2) for the recombinant wild type and V76A were 61.1 and 56.4 µmole min-1 
mg-1, respectively (Table 11).  The Km(NADPH) for the recombinant wild type and V76A 
mutation was 1.55 and 1.56 µM, respectively, whereas Vmax(NADPH) was 26.8 µmole 
min-1 mg-1 for the recombinant wild type and 23.7 µmole min-1 mg-1 for the V76A 
mutation. The Km(NADPH) values of all D31 mutants were slightly reduced compared to 
that of the recombinant wild type. However, this reduction did not vary greatly among the 
D31 mutations which ranged from 0.65 to 0.77 µM, about a 2-fold reduction over the 
recombinant wild type. The Vmax(NADPH) on the other hand, did show larger variation 
among the mutants (Table 11). Dunn et al. (19) as well as Appleman et al. (2) found that 
replacement of the conserved D27 in E. coli reduced the affinity of NADPH by 7 and 3-
fold, respectively. Although this conserved aspartic acid residue is not directly involved 
in binding of NADPH, they argued that the increased rate of dissociation in the mutants 
as well as a shift in the equilibrium that favored nonbinding could be responsible for 
changes in affinity for NADPH.  Based on the Km(NADPH) for all D31 mutations in this 
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study, the effects of the mutations on NADPH seem minimal compared to that of 
dihydrofolate described earlier.  
The functionality of the D31 mutations were overall as hypothesized. However, the 
extent of the reduction in activity of the D31E mutation shows the limited flexibility of 
M. avium DHFR at this position, similar to that of E. coli (18), but different from L. casei 
(7). The kinetic characteristics of the D31 mutations show that, with the exception of the 
D31A mutation, the change in Km(FAH2) was smaller than the change in kcat and kcat/Km 
compared to the recombinant wild type (Table 11). This suggests that the binding of the 
substrate to the mutant enzymes and therefore the formation of the enzyme-substrate (ES) 
complex is not the limiting step in the reaction. The smaller kcat and even smaller kcat/Km 
values of the D31 mutations compared to the recombinant wild type, indicates that the 
portion of the equation that is represented by kcat (dissociation of the ES complex to form 
product) may be the limiting step, resulting in the overall low catalytic efficiency of the 
mutant enzymes (Table 11). The removal of the charged carboxylic acid group by the 
mutations D31Q, D31N and D31L and the introduction of additional hydrophobicity 
could have resulted in local perturbations and contributed to the differences observed in 
the CD spectra of these mutations (Figure 7). 
The functionality of the mutant enzymes was also tested in vivo by assessing their ability 
to restore growth of a DHFR-deficient E. coli. This showed how severely dysfunctional 
these mutant enzymes were. Only the recombinant wild type and the control mutation 
V76A were able to restore growth of the E. coli DHFR deficient strain 
MG1655folA::kan3 to levels comparable to its E. coli MG1655 parent strain in the 
absence of thymidine (Figure 10B). All of the D31 mutants were unable to complement 
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the missing DHFR gene of the deficient strain and subsequently no growth of the E. coli 
DHFR-deficient strain was observed when transformed with plasmid DNA that contained 
the M. avium folA gene with the respective mutation. 
Therefore, one can conclude as hypothesized that aspartic acid 31 has an important 
functional role in catalysis in the M. avium DHFR. Replacing this residue with any other 
amino acid is certain to adversely affect efficient functionality of the enzyme. Both the 
charge of the aspartic acid as well as the spatial and geometric integrity of the binding 
cavity seem necessary for efficient functioning of the enzyme. While the enzyme may be 
able to accommodate local changes without effect on the overall three-dimensional 
structure of the enzyme, those changes, such as the replacement of conserved aspartic 
acid 31 in M. avium and structurally equivalent residues in other organisms could be fatal 
for the enzyme’s normal and efficient functioning. 
Functionality of M. avium conserved leucine 32 (L32) mutants 
The L32 is one of several hydrophobic residues that line the enzyme’s binding cavity, 
which is a common feature for all DHFRs described so far (14, 21, 29, 46, 47, 63). 
This residue is also conserved, but unlike D31 that was only substituted by glutamic acid 
in vertebrates, it is also replaced by glutamine in some bacteria, whereas vertebrates 
either have a phenylalanine or tyrosine in this position (47). 
In this study L32 was substituted by phenylalanine (L32F), alanine (L32A) and aspartic 
acid (L32D). Human DHFR has phenylalanine in the equivalent position. One of the 
differences between bacterial and vertebrate DHFR is that vertebrate DHFRs are very 
resistant to trimethoprim, while bacterial DHFRs are very sensitive (5). Some studies (12, 
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47, 63) have looked at whether phenylalanine in this equivalent position in vertebrates 
plays a role in this difference.  
In contrast to the D31 mutations, which all rendered the enzyme dysfunctional, only one 
of the 3 mutants of L32 caused a significant change in the enzyme’s specific activity.  
The phenylalanine substitution (L32F), which is also hydrophobic, but much larger than 
the leucine residue of the recombinant wild type, did not cause a change in the enzyme’s 
activity with the normal substrate as the percentage relative specific activity over the 
recombinant wild type shows (Table 12).  The L32A mutation, which removed the 
hydrophobic side chain and is much smaller in size, also did not negatively impact the 
enzyme’s normal function.  This mutant still retained 96% of the specific activity of the 
recombinant wild type and was therefore statistically not different from the recombinant 
wild type enzyme (Tables 12 and 13). Only the L32D mutation affected the enzyme’s 
normal reaction with the substrate dihydrofolate negatively. This mutant had only one 
third of the specific activity of the recombinant wild type enzyme and therefore was 
found to be statistically different from the recombinant wild type enzyme (Tables 12 and 
13). These results indicate that unlike the D31 residue, L32 may not be directly involved 
in catalysis.   
The catalytic behavior described before was also mirrored in the mutants’ kinetic 
behavior. The Km(FAH2) for the recombinant wild type, L32F and L32A were 0.7, 0.68 
and 0.96 µM, respectively, and therefore, very similar to each other (Table 14).  Only the 
L32D mutation had a 7-fold increase in Km(FAH2) over the recombinant wild type 
enzyme. Whereas the L32D mutation had a decrease in kcat(FAH2) of only 3-fold over the 
recombinant wild type, the kcat/Km(FAH2) showed a 21-fold decrease (Table 14). The 
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L32F and L32A mutations also did not differ much from the recombinant wild type in kcat 
and Kcat/Km(FAH2); for the L32F mutation this difference was less then 1 for both 
parameters, whereas they were 1.3 and 1.7,  respectively, for the L32A mutation (Table 
14). A similar study by Huang et al. (31), in which the equivalent L28 in E. coli DHFR 
was substituted by tyrosine (L28Y), found no changes in the Michaelis-Menten kinetics 
(Km and kcat) of the mutant compared to the recombinant wild type enzyme. Wagner et al. 
(65) compared the substitution of L28 in E. coli DHFR with phenylalanine (L28F) with 
the reciprocal mutation F31L in mouse DHFR, the equivalent position in vertebrate 
DHFR. The E. coli L28F mutant showed an increased kcat (from 11 to 50 sec-1), but the 
mutation had little effect on Km(FAH2).  On the other hand, the F31L mutation in mouse 
DHFR showed a decreased kcat (from 28 to 4.8 sec-1), but also did not affect Km(FAH2). 
In both cases there was little affect on NADPH.  This study did not observe the increase 
in kcat for the L32F mutation in M. avium DHFR, that was found for the equivalent 
mutation in E. coli DHFR: however, similar to the L28F mutation in E. coli DHFR 
reported by Wagner et al., kcat and Km(FAH2) were not affected much in this study for the 
L32F mutation in M. avium DHFR (Table 14). The L32F mutation in M. avium DHFR 
also did not have an effect on the Km(NADPH) (Table 14). 
The data for the F31L mouse mutant reported by Wagner et al. (65) differ somewhat 
from Chunduru et al. (12) and Prendergast et al. (47), the two latter studies investigating 
the equivalent F31L mutation in human DHFR. Whereas Wagner et al. observed a 
decrease in kcat and no effect on Km, both Chunduru (12) and Prendergast (47), found 
sizeable increases in Km(FAH2); Prendergast (47),  also found an almost 11-fold increase 
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in Km(NADPH).  Overall, this reciprocal mutation in vertebrates, led to a decrease in 
kcat/km of the mutant  (12, 47, 63, 65). 
While this study did not find a change in the L32A mutant’s activity compared to that of 
the recombinant wild type M. avium DHFR, Chunduru et al. (12)   found that the 
equivalent mutant (F31A) in human DHFR had a 4-fold higher Km(FAH2) and that kcat/Km 
was decreased by 4-fold. Nothing was found in the literature for the substitution of 
leucine in this position with aspartic acid. However, the introduction of a charged group 
with the aspartic acid substitution may have adverse effects on interactions in the binding 
cavity. Baccanari et al. (4) found 2 DHFR isozymes in E. coli (RT500) with the only 
difference between them being that one had leucine in position 28, whereas the other had 
arginine in position 28. They argued that interaction between this arginine in position 28 
with the conserved aspartic acid in position 27, probably led to this mutants reduced 
efficiency. The CD spectra (Figure 7) show no difference between the recombinant wild 
type and the L32D mutation. It is therefore possible that the reduction in functionality of 
this mutation could be due to similar interactions in the binding cavity as described by 
Baccanari et al. (4), that led to the change in the mutants’ catalytic and kinetic behavior. 
As previously discussed, X-ray crystal structures of E. coli, L. casei and DHFRs from 
other species reveal interactions of specific residues with substrate and inhibitors. On the 
basis of equivalencies (amino acid alignments), a functional interaction of L32 in M. 
avium with inhibitors was hypothesized. The L32 mutant enzymes were tested in an 
enzyme assay with trimethoprim, a widely used antibacterial agent, for which 
mycobacteria are naturally resistant. Bacterial DHFRs are highly sensitive to 
trimethoprim, whereas vertebrate DHFRs are not (47, 50). It is this characteristic that 
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makes trimethoprim a useful antibacterial agent. Two other deazapteridine antifolates 
were also tested for inhibitory effects against the recombinant wild type and L32 mutants. 
The results as IC50 values are listed in Table 15. The IC50 for trimethoprim of 3869 nM 
for the recombinant wild type compares well with the 4100 nM found the Suling et al. 
(58, 59) for M. avium DHFR. The L32F mutant was not very different from the 
recombinant wild type with an IC50 of 3647 nM for trimethoprim. Although the 
phenylalanine residue is much larger than the leucine of the wild type, this mutation did 
not negatively impact the hydrophobic nature of the area, suggesting that the enzyme is 
more flexible in this position.  The reciprocal mutation in human DHFR (F31L) also did 
not affect that mutant enzyme’s binding of trimethoprim compared to recombinant 
human DHFR (12, 47), which led Prendergast et al. (47) to conclude that the 
phenylalanine in that position in vertebrate DHFR does not account for the difference in 
vertebrate and bacterial DHFR with respect to trimethoprim binding.  The L32A 
mutation’s IC50 for M. avium DHFR in this study was increased about 12-fold over the 
recombinant wild type enzyme (Table 15). The L32A mutant removed the hydrophobic 
residue from this position which may have caused a change in local hydrophobicity. X-
ray crystal structures have shown that the equivalent hydrophobic residue in E. coli and 
L. casei DHFRs are in contact with inhibitors. In their proposed model of the M. avium 
DHFR, Kharkar et al. (33) also point to the role of L32 in interacting with inhibitors. The 
current finding gives support for this role of L32 in M. avium DHFR. This decrease in 
selectivity to trimethoprim by the M. avium L32A mutant is also shown in the equivalent 
mutant (F31A) in human DHFR (12).  
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The L32D mutation in M. avium DHFR led to an almost 7-fold increase in selectivity of 
the mutant to trimethoprim, thereby increasing binding of trimethoprim over the 
recombinant wild type. Given the drastic decrease in normal enzyme function with the 
natural substrate described earlier for the L32D (Table 12) and the increased binding of 
trimethoprim by this mutant, the inhibitor has gained an advantage over the substrate in 
the mutant, whereas the substrate had the competitive advantage in the recombinant wild 
type enzyme. The introduction of the charge with the aspartic acid in the L32D mutation 
seems to interact or stabilize trimethoprim, but not the substrate dihydrofolate. In the 
known DHFR X-ray crystal structures of L. casei and E. coli the p-aminobenzoic acid 
ring of folate is closely aligned with L27 and L28, respectively (38, 39). Kharkar et al. 
(33) proposed the same for L32 in their model of the M. avium DHFR. The L32D 
mutation in M. avium DHFR did not only remove the hydrophobic residue that stabilized 
the folate, but introduced a charge that may destabilize folate in the binding cavity, 
thereby negatively affecting the folate activity. Structurally trimethoprim does not have 
the hydrophobic ring of folate, but protruding methoxy groups (Figure 2) that might 
interact with aspartic acid to stabilize the inhibitor. 
Two 2,4-diamino-5-methyl-5-deazapteridines (SRI compounds 8858 and 20730) (Figure 
3) that have previously been shown to be active against M. avium, (59) have also been 
tested against the L32 mutants of M. avium DHFR in comparison to the recombinant wild 
type. The IC50 values for these compounds are listed in Table 15.  Compared to 
trimethoprim both compounds were highly active against the recombinant wild type 
DHFR enzyme. The IC50 for compound 8858 was 1.03 nM for the recombinant wild type, 
whereas for compound 20730 it was 1.96 nM. This represents an increase in selectivity of 
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over 3000 and almost 2000-fold, respectively. This study used the salt forms of the 
deazapteridines that were previously tested by Suling et al. (59) in the lipophilic form. 
The IC50 value of the lipophilic compound 8686 (salt form 8858) was 0.84 nM, and that 
of the lipophilic compound 20094 (salt form 20730) was 1.0 nM for the recombinant wild 
type M. avium DHFR.  The IC50 values for compound 8858 tested in this study compares 
well with that obtained by Suling et al. (59)  for the lipophilic form, while compound 
20730 tested here was almost double the IC50 of the lipophilic form tested by Suling et al. 
(59) . The findings of this study are further support of the activity of these deazapteridine 
derivatives against M. avium DHFR.   
All L32 mutants in this study showed increased selectivity compared to trimethoprim, 
further support the potency of these compounds for M. avium DHFR. However, 
compared to the recombinant wild type, there is a gradual decrease in selectivity in the 
mutants for both these compounds. This increase proceeds in the order L32F > L32D > 
L32A. Although there was no difference in IC50 between the recombinant wild type and 
the L32F mutant with respect to trimethoprim, there was almost a 15- and 20-fold 
difference in IC50 between the recombinant wild type the L32F mutant for the compounds 
8858 and 20730, respectively (Table 15). Even though the phenylalanine in this position 
would not change the hydrophobic nature of the surroundings, its large size might be in 
too close contact with the substitutent groups R1 and R5 on the phenyl ring (Figure 3), 
thereby causing steric interference. The L32 side chain in the wild type enzyme is much 
smaller and may accommodate the substitutent groups on the phenyl ring of these 
compounds much better. 
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The L32D mutation of the M. avium DHFR showed an IC50 of 69 nM for compound 8858 
and 134 nM for compound 20730. For compound 8858 this was about 8-fold lower than 
trimethoprim; compound 20730 was about 4-fold lower than trimethoprim. Nevertheless, 
both compounds 8858 and 20730 that were highly effective against the recombinant wild 
type enzyme, were now respectively 67-and 68-fold less effective in the L32D mutant of 
M. avium DHFR. As discussed earlier the trimethoprim seems to have been stabilized in 
the binding cavity by the charge group of the aspartic acid in the L32D mutation, but that 
was not the case for folate and it doesn’t seem to be the case for the ether compounds 
8858 or 20730. The position of the phenyl ring with substituents R1 and R5 in close 
proximity to the charge carboxylic acid in position 32, formally occupied by a smaller 
hydrophilic residue, could also lead to steric interferences and affect binding of these 
compounds.  
The last mutation in this series, L32A, that was highly insensitive against trimethoprim 
with an IC50 of 45067 nM,  had an IC50 of 507 nM for compound 8858 and 861 nM for 
compound 20730.  Despite the fact that the L32A mutation of M. avium DHFR seems to 
have had an increased sensitivity for the SRI compounds over trimethoprim, the 
difference between this mutation and the recombinant wild type was only about 12-fold 
for trimethoprim, but it was 492-fold for compound 8858 and 439-fold for compound 
20730.  In addition to removing the hydrophobic side chain of L32 present in the wild 
type, the alanine residue in the L32A mutant has the smallest side chain of all the mutants 
tested. Therefore there is little opportunity for either interference or interaction with the 
SRI compounds. The favorable interaction and stabilizing effect of the hydrophobic L32 
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residue is absent in the L32A mutant and therefore the large difference in IC50 between 
the recombinant wild type and the L32A mutants for both compounds 8858 and 20730.  
In summary the hypothesis, that was based on previous findings in E. coli, L. casei and 
DHFR’s of other species, that L32 in M. avium DHFR plays a functional role in the 
binding of antifolates such as trimethoprim and the 2,4- diaminodeazapteridines 
described earlier and tested in this study, was supported by the findings of this study. 
However, unlike D31 in M. avium DHFR, L32 substitution by another hydrophobic 
residue (L32F) did not affect the enzymes normal function, even though phenylalanine is 
larger than the wild type leucine residue in position 32. This indicates that leucine may 
not play a role or not a direct role in catalysis. The rather high reduction in enzyme 
function by the L32D mutation could therefore be as a result of secondary factors. This 
substituted aspartic acid may interact with the residue D31, which has been shown in this 
study and in others to affect enzyme functionality. 
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CHAPTER V 
CONCLUSION 
The finding of this study for M. avium DHFR is consistent with what is currently known 
about the highly conserved binding cavity aspartic acid residue in E. coli, L. casei and 
other DHFR’s. Aspartic acid 31 in M. avium DHFR plays a functional role in catalysis. 
Modification of size and charge (D31A, D31E and D31Q) and charge (D31N and D31L) 
resulted in a significant reduction of normal enzyme activity. 
The findings of this study also support the hypothesis that L32 plays a functional role in 
the binding of antifolate inhibitors such as trimethoprim and 2,4-deazapteridines. It has 
been shown that modification of L32 in M. avium DHFR (L32D) made the enzyme more 
sensitive to trimethoprim, a current drug for which the organism is naturally resistant. It 
has also been shown that modifications of L32 in M. avium DHFR (L32A and L32D) 
have decreased selectivity of the enzyme for current potential inhibitors such as the 2,4-
diaminodeazapteridines. 
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